<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T05:29:09Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:4621059" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:4621059</identifier>
        <datestamp>2015-10-29</datestamp>
        <setSpec>plosone</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">PLoS One</journal-id>
              <journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id>
              <journal-id journal-id-type="publisher-id">plos</journal-id>
              <journal-id journal-id-type="pmc">plosone</journal-id>
              <journal-title-group>
                <journal-title>PLoS ONE</journal-title>
              </journal-title-group>
              <issn pub-type="epub">1932-6203</issn>
              <publisher>
                <publisher-name>Public Library of Science</publisher-name>
                <publisher-loc>San Francisco, CA USA</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC4621059</article-id>
              <article-id pub-id-type="pmcid">PMC4621059</article-id>
              <article-id pub-id-type="pmc-uid">4621059</article-id>
              <article-id pub-id-type="pmid">26501782</article-id>
              <article-id pub-id-type="pmid">26501782</article-id>
              <article-id pub-id-type="doi">10.1371/journal.pone.0141002</article-id>
              <article-id pub-id-type="publisher-id">PONE-D-14-19585</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Research Article</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in Tanzania</article-title>
                <alt-title alt-title-type="running-head">Pharmacokinetics of INH PZA and EMB in TB Patients</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" equal-contrib="yes">
                  <name>
                    <surname>Denti</surname>
                    <given-names>Paolo</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author" equal-contrib="yes">
                  <name>
                    <surname>Jeremiah</surname>
                    <given-names>Kidola</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff002">
                    <sup>2</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff003">
                    <sup>3</sup>
                  </xref>
                  <xref rid="cor001" ref-type="corresp">*</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Chigutsa</surname>
                    <given-names>Emmanuel</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="author-notes" rid="currentaff001">
                    <sup>Â¤</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Faurholt-Jepsen</surname>
                    <given-names>Daniel</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff004">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>PrayGod</surname>
                    <given-names>George</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff003">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Range</surname>
                    <given-names>Nyagosya</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff005">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Castel</surname>
                    <given-names>Sandra</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wiesner</surname>
                    <given-names>Lubbe</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hagen</surname>
                    <given-names>Christian Munch</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff006">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Christiansen</surname>
                    <given-names>Michael</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff006">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Changalucha</surname>
                    <given-names>John</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff003">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>McIlleron</surname>
                    <given-names>Helen</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Friis</surname>
                    <given-names>Henrik</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff004">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Andersen</surname>
                    <given-names>Aase Bengaard</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff002">
                    <sup>2</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff007">
                    <sup>7</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="aff001">
                <label>1</label>
                <addr-line>Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa</addr-line>
              </aff>
              <aff id="aff002">
                <label>2</label>
                <addr-line>Department of Infectious Diseases, Odense University Hospital, Odense, Denmark</addr-line>
              </aff>
              <aff id="aff003">
                <label>3</label>
                <addr-line>National Institute for Medical Research, Mwanza Medical Research Centre, Mwanza, Tanzania</addr-line>
              </aff>
              <aff id="aff004">
                <label>4</label>
                <addr-line>Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Copenhagen, Denmark</addr-line>
              </aff>
              <aff id="aff005">
                <label>5</label>
                <addr-line>National Institute for Medical Research, Muhimbili Research Centre, Dar Es Salaam, Tanzania</addr-line>
              </aff>
              <aff id="aff006">
                <label>6</label>
                <addr-line>Department for Congenital Disorders, Statens Serum Institut, Copenhagen, Denmark</addr-line>
              </aff>
              <aff id="aff007">
                <label>7</label>
                <addr-line>Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark</addr-line>
              </aff>
              <contrib-group>
                <contrib contrib-type="editor">
                  <name>
                    <surname>Subbian</surname>
                    <given-names>Selvakumar</given-names>
                  </name>
                  <role>Editor</role>
                  <xref ref-type="aff" rid="edit1"/>
                </contrib>
              </contrib-group>
              <aff id="edit1">
                <addr-line>Public Health Research Institute at RBHS, UNITED STATES</addr-line>
              </aff>
              <author-notes>
                <fn fn-type="COI-statement" id="coi001">
                  <p><bold>Competing Interests: </bold>Dr. Emmanuel Chigutsa was a PhD student at the University of Cape Town while he first contributed to this work. After he graduated in 2013, Dr. Chigutsa moved to Eli Lilly and Company as post-doctoral fellow. However, Eli Lilly and Company was not involved in this work, since the Danish Ministry of Foreign Affairs (DANIDA, DFC file no. 09-026RH) through the Denmarkâs International Development Cooperation entirely supported this study. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.</p>
                </fn>
                <fn fn-type="con" id="contrib001">
                  <p>Conceived and designed the experiments: ABA NR HF HM JC. Performed the experiments: KJ GP LW SC DFJ EC PD CMH MC. Analyzed the data: KJ PD EC DFJ. Wrote the paper: KJ PD. Contributed to interpretation of the results and comments on drafts and approved the final version: ABA NR HF HM KJ GP LW SC DFJ EC JC PD MC CMH.</p>
                </fn>
                <fn fn-type="current-aff" id="currentaff001">
                  <label>Â¤</label>
                  <p>Current Address: Eli Lilly and Company, Indianapolis, Indiana, United State of America</p>
                </fn>
                <corresp id="cor001">* E-mail: <email>jkidola@gmail.com</email></corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>26</day>
                <month>10</month>
                <year>2015</year>
              </pub-date>
              <pub-date pub-type="collection">
                <year>2015</year>
              </pub-date>
              <volume>10</volume>
              <issue>10</issue>
              <elocation-id>e0141002</elocation-id>
              <history>
                <date date-type="received">
                  <day>1</day>
                  <month>5</month>
                  <year>2014</year>
                </date>
                <date date-type="accepted">
                  <day>2</day>
                  <month>10</month>
                  <year>2015</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>Â© 2015 Denti et al</copyright-statement>
                <copyright-year>2015</copyright-year>
                <copyright-holder>Denti et al</copyright-holder>
                <license xlink:href="http://creativecommons.org/licenses/by/4.0/">
                  <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:type="simple" xlink:href="pone.0141002.pdf"/>
              <abstract>
                <p>Exposure to lower-than-therapeutic levels of anti-tuberculosis drugs is likely to cause selection of resistant strains of <italic>Mycobacterium tuberculosis</italic> and treatment failure. The first-line anti-tuberculosis (TB) regimen consists of rifampicin, isoniazid, pyrazinamide, and ethambutol, and correct management reduces risk of TB relapse and development of drug resistance. In this study we aimed to investigate the effect of standard of care plus nutritional supplementation versus standard care on the pharmacokinetics of isoniazid, pyrazinamide and ethambutol among sputum smear positive TB patients with and without HIV. In a clinical trial in 100 Tanzanian TB patients, with or without HIV infection, drug concentrations were determined at 1 week and 2 months post initiation of anti-TB medication. Data was analysed using population pharmacokinetic modelling. The effect of body size was described using allometric scaling, and the effects of nutritional supplementation, HIV, age, sex, CD4+ count, weight-adjusted dose, NAT2 genotype, and time on TB treatment were investigated. The kinetics of all drugs was well characterised using first-order elimination and transit compartment absorption, with isoniazid and ethambutol described by two-compartment disposition models, and pyrazinamide by a one-compartment model. Patients with a slow NAT2 genotype had higher isoniazid exposure and a lower estimate of oral clearance (15.5 L/h) than rapid/intermediate NAT2 genotype (26.1 L/h). Pyrazinamide clearance had an estimated typical value of 3.32 L/h, and it was found to increase with time on treatment, with a 16.3% increase after the first 2 months of anti-TB treatment. The typical clearance of ethambutol was estimated to be 40.7 L/h, and was found to decrease with age, at a rate of 1.41% per year. Neither HIV status nor nutritional supplementations were found to affect the pharmacokinetics of these drugs in our cohort of patients.</p>
              </abstract>
              <funding-group>
                <funding-statement>This work was supported by Danish Ministry of Foreign Affairs (DANIDA, DFC file no. 09-026RH) through the Denmarkâs International Development Cooperation. ABA is the guarantor of the paper. Furthermore it was in part supported by The National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number UM1 AI068634, UM1 AI068636 and UM1 AI106701. HM is supported in part by the National Research Foundation of South Africa (Grant Number 90729). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
              </funding-group>
              <counts>
                <fig-count count="7"/>
                <table-count count="5"/>
                <page-count count="19"/>
              </counts>
              <custom-meta-group>
                <custom-meta id="data-availability">
                  <meta-name>Data Availability</meta-name>
                  <meta-value>Data are available upon request to the corresponding author due to ethical restrictions imposed by the Medical Research Coordinating Committee (MRCC) of the National Institute for Medical Research (NIMR) in Tanzania. Permission from the MRCC must be obtained before this data can be transferred or shared.</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <title>Data Availability</title>
              <p>Data are available upon request to the corresponding author due to ethical restrictions imposed by the Medical Research Coordinating Committee (MRCC) of the National Institute for Medical Research (NIMR) in Tanzania. Permission from the MRCC must be obtained before this data can be transferred or shared.</p>
            </notes>
          </front>
          <body>
            <sec sec-type="intro" id="sec001">
              <title>Introduction</title>
              <p>The aim of anti-tuberculosis (TB) treatment is to provide a safe, effective, and fast acting therapy [<xref rid="pone.0141002.ref001" ref-type="bibr">1</xref>]. Isoniazid, pyrazinamide, and ethambutol constitute important companion drugs used in a standard first-line short-course regimen together with rifampicin [<xref rid="pone.0141002.ref002" ref-type="bibr">2</xref>] and are believed to eradicate aerobic, anaerobic, microaerophilic, and drug tolerant persisting bacteria [<xref rid="pone.0141002.ref003" ref-type="bibr">3</xref>]. While isoniazid and pyrazinamide have bactericidal activity against <italic>M</italic>. <italic>tuberculosis</italic>, ethambutol is considered a bacteriostatic drug, though it may have bactericidal activity when given in higher doses [<xref rid="pone.0141002.ref002" ref-type="bibr">2</xref>]. Treatment success rates of 88% were reported in Tanzania in 2011 using this regimen, thereby meeting the 85% target set by the World Health Assembly in 1993 [<xref rid="pone.0141002.ref004" ref-type="bibr">4</xref>, <xref rid="pone.0141002.ref005" ref-type="bibr">5</xref>]. However, multidrug-resistance (MDR-TB) is emerging (1.1% of newly diagnosed TB cases in Tanzania are MDR-TB) and may over time threat the standard first-line regimen [<xref rid="pone.0141002.ref004" ref-type="bibr">4</xref>, <xref rid="pone.0141002.ref005" ref-type="bibr">5</xref>]. Previous studies have shown that low plasma anti-TB drug concentrations may result in treatment failure [<xref rid="pone.0141002.ref006" ref-type="bibr">6</xref>, <xref rid="pone.0141002.ref007" ref-type="bibr">7</xref>] and low plasma concentrations of rifampicin and isoniazid have been associated with MDR-TB [<xref rid="pone.0141002.ref008" ref-type="bibr">8</xref>, <xref rid="pone.0141002.ref009" ref-type="bibr">9</xref>]. Wide variability is reported in the pharmacokinetics (PK) of isoniazid, pyrazinamide, and ethambutol [<xref rid="pone.0141002.ref010" ref-type="bibr">10</xref>â<xref rid="pone.0141002.ref012" ref-type="bibr">12</xref>], with factors such as age and HIV status and antiretroviral treatment (ART) possibly affecting TB drug concentrations [<xref rid="pone.0141002.ref012" ref-type="bibr">12</xref>â<xref rid="pone.0141002.ref017" ref-type="bibr">17</xref>]. Furthermore, malnutrition also seems to affect drug exposure by decreasing total clearance and increasing plasma half-life [<xref rid="pone.0141002.ref018" ref-type="bibr">18</xref>]. Nutritional rehabilitation of children with kwashiorkor has been reported to enhance isoniazid clearance [<xref rid="pone.0141002.ref019" ref-type="bibr">19</xref>], but the influence of administering nutritional supplementation to adult TB patients is unclear. We therefore conducted a randomized clinical trial in Mwanza, Tanzania to examine the effect of nutritional supplementation on the pharmacokinetics of first-line anti-TB drugs in a cohort of pulmonary TB patients with or without HIV. We recently reported the positive effect on a nutritional supplementation on rifampicin exposure in the HIV co-infected patients (all ART naÃ¯ve) [<xref rid="pone.0141002.ref020" ref-type="bibr">20</xref>]. In this analysis we aimed to investigate the effect of standard of care plus nutritional supplementation vs. standard care on PK of isoniazid, pyrazinamide, and ethambutol among sputum smear positive TB patients with and without HIV. We also explored the effect of other covariates, including NAT2 genotype on the PK of isoniazid.</p>
            </sec>
            <sec sec-type="materials|methods" id="sec002">
              <title>Materials and Methods</title>
              <sec id="sec003">
                <title>Ethics Statement</title>
                <p>Ethical permission to conduct the study was granted by the Medical Research Coordinating Committee (MRCC) of the National Institute for Medical Research (NIMR) in Tanzania. Oral and written information were provided in Swahili to all participants prior to obtaining informed oral and written consent. Written consent was obtained from parents/legal guardians of participants aged 15â17 years.</p>
              </sec>
              <sec id="sec004">
                <title>Study design, setting, and participants</title>
                <p>The study was an open-label randomized clinical trial (ControlledTrials.com: ISRCTN 16552219) among 100 sputum smear positive TB patients, and details about the protocol are available as supplementary information) (<xref rid="pone.0141002.s001" ref-type="supplementary-material">S1 Protocol</xref>). The study was conducted in the city of Mwanza, Tanzania between September 2010 and August 2011. Mwanza is the second largest city in the country and is the region with the second highest number of TB case notification (9.3%) after Dar es Salaam (21.9%) [<xref rid="pone.0141002.ref005" ref-type="bibr">5</xref>]. The study recruited newly diagnosed sputum positive pulmonary TB patients aged 15 years or above. HIV-infected patients on ART, pregnant women, critically ill patients not likely to survive &gt; 48 hours, and non-residents of Mwanza City were excluded.</p>
              </sec>
              <sec id="sec005">
                <title>TB medication and intervention</title>
                <p>The TB patients were administered TB medication according to the National Tuberculosis and Leprosy Programme (NTLP) treatment guidelines [<xref rid="pone.0141002.ref005" ref-type="bibr">5</xref>], and those found co-infected with HIV were managed according to National guidelines for the management of HIV and AIDS policy [<xref rid="pone.0141002.ref021" ref-type="bibr">21</xref>]. The antiâTB drugs prescribed were formulated in fixedâdose combination (FDC) tablets containing isoniazid (75 mg), rifampicin (150 mg), pyrazinamide (400 mg), and ethambutol (275 mg) (Sandoz Pvt Ltd, India). Dosing was adjusted based on body weight: 3 tablets for patients weighing up to 50 kg, and 4 tablets for those weighing more than 50 kg. The patients were randomized to either receive or not receive nutritional supplementation in the form of biscuits (Compact A/S, Bergen, Norway) containing high-energy (1000 kcal) and vitamin/minerals according to trial protocol [<xref rid="pone.0141002.ref020" ref-type="bibr">20</xref>]. A complete list of nutrients content is shown in <bold><xref rid="pone.0141002.t001" ref-type="table">Table 1</xref>.</bold>
</p>
                <table-wrap id="pone.0141002.t001" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0141002.t001</object-id>
                  <label>Table 1</label>
                  <caption>
                    <title>Nutrients composition of the intervention used in the trial.</title>
                  </caption>
                  <alternatives>
                    <graphic id="pone.0141002.t001g" xlink:href="pone.0141002.t001"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" valign="middle" span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="center" rowspan="1" colspan="1">1 daily biscuit with the following micro nutrients<xref rid="t001fn001" ref-type="table-fn"><sup>a</sup></xref>
</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">Vitamin A(5000IU)</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">Vitamin B<sub>1</sub> (20mg)</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">Vitamin B<sup>2</sup> (20mg)</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">Vitamin B<sub>6</sub> (25mg)</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">Vitamin B<sub>12</sub> (50mg)</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">Folic acid (0.8mg)</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">Niacin (40mg)</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">Vitamin C (200mg)</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">Vitamin E (60mg)</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">Vitamin D<sub>3</sub> (200iu)</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">Selenium 0.2 mg</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">Copper (5mg)</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">Zinc (30mg)</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">Plus 4 additional daily biscuit with energy-protein</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                  <table-wrap-foot>
                    <fn id="t001fn001">
                      <p><sup>a</sup>Duration of intervention 60 days</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="sec006">
                <title>Data collection</title>
                <p>A standardised questionnaire was used to solicit demographic characteristics, previous TB history, and use of alcohol. Anthropometric measurements including weight and height were obtained at each visit. All participants had a chest x-ray taken at recruitment and two independent radiographers confirmed abnormalities.</p>
              </sec>
              <sec id="sec007">
                <title>Laboratory analyses</title>
                <p>At recruitment, venous blood samples were collected. CD4+ lymphocyte count was analysed using a CoulterÂ® Epics XL-MCLâ¢ Flow Cytometer (Beckman Coulter, Brea, CA). Haemoglobin level and white blood cell counts were analysed using haematological Coulter AcT 5 diff, (Beckman Coulter, Brea, CA). HIV status was determined on two rapid tests done in parallel (SD Bioline HIV-1/2 3.0, Standard Diagnostics Inc., Kyonggi-do, South Korea; Determine HIV-1/HIV-2, Inverness Medical Innovations Inc., Delaware, USA). Discordant HIV test results were resolved using HIV UNIFORM II ELISA (Organon Teknia Ltd, Boxtel, Netherlands),</p>
              </sec>
              <sec id="sec008">
                <title>Pharmacokinetic plasma sample collection, processing and analysis</title>
                <p>Patients were scheduled for plasma sample collection on two occasions: at one week and two months post-initiation of anti-TB medication. One day before blood sampling patients were instructed to fast overnight, and on the morning of the PK visit, the study nurse administered the anti-TB drugs according to body weight. Whole blood was collected in 5 mL of lithium heparin tubes at 2, 4, and 6 hours post-dose. Samples were immediately centrifuged at 3000 rpm for 10 min to separate the plasma and transferred to -80Â°C within 30 minutes. The plasma samples were then transported in dry ice to the Division of Clinical Pharmacology, University of Cape Town, South Africa, for determination of isoniazid, pyrazinamide, and ethambutol concentrations using validated tandem mass spectrometry high-performance liquid chromatography (LC-MS/MS) methods. An AB Sciex API mass spectrometer was operated in the multiple reactions monitoring (MRM) mode. The assays were validated over the concentration range of 0.112 to 26 mg/L for isoniazid, 0.203 to 81.1 mg/L for pyrazinamide and 0.081 to 5.18 mg/L for ethambutol. The mean percentage accuracies during inter-day sample analysis at low, medium, and high quality control levels, respectively, were 98.2%, 99.3%, and 94.7% for isoniazid, 97.8%, 102.1%, and 100.5% for pyrazinamide, and 99%, 101.3%, and 99.6% for ethambutol. The precision coefficient of variation for determination at low, medium, and high quality control level for both pyrazinamide and ethambutol was less than 4% and for isoniazid less than 5%. Concentrations below the validation range of the assay were reported as below the lower limit of quantification (BLQ).</p>
              </sec>
              <sec id="sec009">
                <title>DNA extraction and NAT2 analysis</title>
                <p>Serum aliquots for N-acetyltransferase-2 (NAT2) genotype were kept under -80Â°C until analyzed. Genotyping was carried out at the Statens Serum Institut, Copenhagen, DK after DNA was extracted from blood using QIAamp DNA minikit (Qiagen GmbH, Hilden, Germany). An annealing temperature of 60Â°C was used in all polymerase chain reactions (PCR). The PCR products were sequenced using BigDye Terminator v1.1 Cycle Resequencing (<italic>ABI</italic>), and analyzed on an ABI3730 DNA Analyzer. The resulting sequences were compared to NCBI accession no. NG_012246.1 <italic>N</italic>-acetyltransferase-2 (NAT2) using Sequencer 5.0 software (Gene Codes, Ann Arbor, USA). NAT2 haplotypes were based on dbSNP IDs: c.282C&gt;T (rs1041983), c.341T&gt;C (rs1801280), c.481C&gt;T (rs1799929), c.590G&gt;A (rs1799930), c.803A&gt;G (rs1208) and c.857G&gt;A (rs1799931) and the acetylator phenotype was inferred using NAT2PRED (<ext-link ext-link-type="uri" xlink:href="http://nat2pred.rit.albany.edu/">http://nat2pred.rit.albany.edu/</ext-link>).</p>
              </sec>
              <sec id="sec010">
                <title>Nonlinear mixed-effects modelling analysis</title>
                <p>Nonlinear mixed-effects modelling was employed to interpret the data with the software NONMEM 7.3 [<xref rid="pone.0141002.ref022" ref-type="bibr">22</xref>], and the algorithm First-Order Conditional Estimation with eta-epsilon interaction. Pirana, Perl-speaks-NONMEM, and xpose4 were used to aid the modelling process and prepare model diagnostics [<xref rid="pone.0141002.ref023" ref-type="bibr">23</xref>]. The modelling procedure was similar for all drugs, as outlined below. Several structural models were tested: one- and two-compartment disposition kinetics with first-order elimination and several approaches for absorption: first-order, lagged first-order and transit compartment absorption [<xref rid="pone.0141002.ref024" ref-type="bibr">24</xref>]. The statistical model assumed log-normal distribution for the between-subject andâoccasion random effects, and a combined additive and proportional structure for the residual unexplained variability, with the additive component of the error bound to be at least 20% of the lower limit of quantification (LLOQ). Allometric scaling with either total body weight (WT) or fat-free mass (FFM) was applied to all clearances (CL and Q) and volumes of distribution (V<sub>c</sub> and V<sub>p</sub>), as advocated by Anderson and Holford [<xref rid="pone.0141002.ref025" ref-type="bibr">25</xref>]. The effect of other covariates was tested and included in the model based on significant decreases (p&lt;0.05) in the Objective Function Value (OFV) and physiological plausibility. Covariates tested for effects on PK parameters were: HIV co-infection, nutritional supplementation, age, sex, CD4+ lymphocyte count, daily weight-adjusted dose, and time on TB treatment. Additionally, NAT2 acetylator status was tested on isoniazid PK. The OFV, goodness of fit plots, and Visual Predictive Checks (VPC) guided model development. The robustness of the final parameter estimates was assessed with a non-parametric bootstrap. The post-hoc individual parameter estimates from the final model were used to obtain the exposure parameters C<sub>max</sub> and AUC<sub>0-24</sub>. These individual values were calculated to provide summary values for comparison with previous studies, but they were not used. with the purpose of statistical inference, since they are dependent on the model and they are affected by statistical shrinkage (especially C<sub>max</sub>)[<xref rid="pone.0141002.ref026" ref-type="bibr">26</xref>].</p>
              </sec>
            </sec>
            <sec sec-type="results" id="sec011">
              <title>Results</title>
              <p>A total of 100 newly diagnosed pulmonary TB patients were enrolled in the study <bold>(<xref rid="pone.0141002.g001" ref-type="fig">Fig 1</xref>)</bold>. The sex and HIV status distributions were almost even, with 42% (n = 42) women and 50 HIV co-infected. The median (IQR) age was 35 years (29; 40) and weight was 51.9 kg (48.2; 57.3). As many as 48 subjects were classified as NAT2 slow acetylators, 48 as intermediate, and 2 as rapid acetylators, while the acetylator status of 2 subjects could not be determined. Baseline characteristics are shown in <bold><xref rid="pone.0141002.t002" ref-type="table">Table 2</xref>.</bold>
</p>
              <fig id="pone.0141002.g001" orientation="portrait" position="float">
                <object-id pub-id-type="doi">10.1371/journal.pone.0141002.g001</object-id>
                <label>Fig 1</label>
                <caption>
                  <title>Flow chart for pulmonary TB-positive patients randomized to receive a nutritional supplement or no supplement and followed for the effects of nutritional supplementation on Isoniazid, Pyrazinamide and Ethambutal exposure at the end of the second month of intensive phase of treatment.</title>
                </caption>
                <graphic xlink:href="pone.0141002.g001"/>
              </fig>
              <table-wrap id="pone.0141002.t002" orientation="portrait" position="float">
                <object-id pub-id-type="doi">10.1371/journal.pone.0141002.t002</object-id>
                <label>Table 2</label>
                <caption>
                  <title>Baseline characteristics of 100 pulmonary sputum smear positive patients starting TB treatment.</title>
                </caption>
                <alternatives>
                  <graphic id="pone.0141002.t002g" xlink:href="pone.0141002.t002"/>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th align="center" rowspan="1" colspan="1">Characteristics</th>
                        <th align="center" rowspan="1" colspan="1">Values<xref rid="t002fn001" ref-type="table-fn"><sup>a</sup></xref>
</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Age (years)</td>
                        <td align="right" rowspan="1" colspan="1">35 (29; 40)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Sex (Males)</td>
                        <td align="right" rowspan="1" colspan="1">58 (58.0)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Weight (kg)</td>
                        <td align="right" rowspan="1" colspan="1">51.9 (48.3; 57.3)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Body mass index (kg/m<sup>2</sup>)</td>
                        <td align="right" rowspan="1" colspan="1">18.8 (17.3; 19.9)</td>
                      </tr>
                      <tr>
                        <td align="justify" rowspan="1" colspan="1">Haemoglobin (g/dL)<xref rid="t002fn002" ref-type="table-fn"><sup>b</sup></xref>
</td>
                        <td align="right" rowspan="1" colspan="1">111 (93; 125)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">White blood cell (x 10<sup>9</sup>/L)<xref rid="t002fn002" ref-type="table-fn"><sup>b</sup></xref>
</td>
                        <td align="right" rowspan="1" colspan="1">6.6 (4.6; 9.1)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">CD4+ count (cell/Î¼L)<xref rid="t002fn002" ref-type="table-fn"><sup>b</sup></xref>
</td>
                        <td align="right" rowspan="1" colspan="1">375 (160; 642)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">HIV infected</td>
                        <td align="right" rowspan="1" colspan="1">50 (50.0)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">TB cavitations present</td>
                        <td align="right" rowspan="1" colspan="1">28 (32.2)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Fasting blood glucose (mmol/L)</td>
                        <td align="right" rowspan="1" colspan="1">6 (5.4; 6.6)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Nutritional supplementation</td>
                        <td align="right" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Â Â Â Â No Supplementation</td>
                        <td align="right" rowspan="1" colspan="1">49 (49.0)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Â Â Â Â Received supplementation</td>
                        <td align="right" rowspan="1" colspan="1">51 (51.0)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">NAT2 phenotype</td>
                        <td align="right" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Â Â Â Â Slow</td>
                        <td align="right" rowspan="1" colspan="1">48(48.0)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Â Â Â Â Intermediate</td>
                        <td align="right" rowspan="1" colspan="1">48 (48.0)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Â Â Â Â Rapid</td>
                        <td align="right" rowspan="1" colspan="1">2 (2.0)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Â Â Â Â Unknown</td>
                        <td align="right" rowspan="1" colspan="1">2 (2.0)</td>
                      </tr>
                    </tbody>
                  </table>
                </alternatives>
                <table-wrap-foot>
                  <fn id="t002fn001">
                    <p><sup>a</sup>Data are median (IQR) or n (%).</p>
                  </fn>
                  <fn id="t002fn002">
                    <p><sup>b</sup>The total number of observations was not 100 due to missing values.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <p>A total of 192 isoniazid PK profiles were obtained from 100 patients, based on 574 plasma concentration measurements, three of which were BLQ. The final structural model was a two-compartment disposition with transit compartment absorption. The data did not support significantly different estimates for the absorption rate constant (k<sub>a</sub>) and for the rate constants between the transit compartments (k<sub>tr</sub>), so the absorption model was simplified. Fat-free mass (FFM) was found to be the most suitable size descriptor for allometric scaling. The model supported between-subject variability in clearance and between-occasion variability in bioavailability and mean absorption transit time (MTT). The population pharmacokinetic final parameter estimates are shown in <bold><xref rid="pone.0141002.t003" ref-type="table">Table 3</xref></bold>, and a visual predictive check is shown in <bold><xref rid="pone.0141002.g002" ref-type="fig">Fig 2</xref></bold>.The model detected a significant effect of NAT2 acetylator status on CL (51.4 points improvement in OFV, p&lt;10<sup>â6</sup>). Subjects with slow NAT2 genotype had a lower clearance (15.5 L/h) compared to rapid or intermediate NAT2 (26.1 L/h). For the two subjects with undetermined NAT2 acetylator status, their values were imputed using a mixture model taking into account both their observed isoniazid concentrations and the relative frequency of each genotype in the rest of the study population, as suggested in Keizer <italic>et al</italic>. [<xref rid="pone.0141002.ref027" ref-type="bibr">27</xref>]. The model did not detect significant effects of HIV or nutritional supplementation on clearance or bioavailability. The individual values of C<sub>max</sub> and AUC<sub>0-24h</sub>, stratified by NAT2 genotype are shown in <bold><xref rid="pone.0141002.g003" ref-type="fig">Fig 3</xref></bold>. Among the slow NAT2 acetylators, median AUC<sub>0-24</sub> and C<sub>max</sub> were 17.1 hÂ·mg/L (IQR: 14.7; 21.2) and 3.53 mg/L (IQR: 3.09; 3.83), respectively. The subjects categorised as rapid or intermediate NAT2 acetylators achieved lower median AUC<sub>0-24</sub> and C<sub>max</sub>: 9.89 hÂ·mg/L (IQR: 7.99; 12.1) and 3.03 mg/L (IQR: 2.76; 3.49), respectively.</p>
              <fig id="pone.0141002.g002" orientation="portrait" position="float">
                <object-id pub-id-type="doi">10.1371/journal.pone.0141002.g002</object-id>
                <label>Fig 2</label>
                <caption>
                  <title>Visual predictive check (VPC) for isoniazid concentration versus time, stratified by NAT2 acetylator status (extensive and intermediate on the left, slow on the right).</title>
                  <p>The circles represent the original data, the dashed and solid lines are the 5<sup>th</sup>, 50<sup>th</sup>, and 95<sup>th</sup> percentiles of the original data, while the shaded areas are the corresponding 95% confidence intervals for the same percentiles, as predicted by the model.</p>
                </caption>
                <graphic xlink:href="pone.0141002.g002"/>
              </fig>
              <fig id="pone.0141002.g003" orientation="portrait" position="float">
                <object-id pub-id-type="doi">10.1371/journal.pone.0141002.g003</object-id>
                <label>Fig 3</label>
                <caption>
                  <title>Box and whisker plots showing isoniazid exposure vs. time NAT2 acetylator status (grouped as rapid or intermediate together vs. slow).</title>
                  <p>The left panel displays AUC<sub>0-24</sub> and the right panel C<sub>max</sub>. The dots represent individual values. Since for most subjects 2 PK profiles were available, geometric mean was used to summarize the individual values.</p>
                </caption>
                <graphic xlink:href="pone.0141002.g003"/>
              </fig>
              <table-wrap id="pone.0141002.t003" orientation="portrait" position="float">
                <object-id pub-id-type="doi">10.1371/journal.pone.0141002.t003</object-id>
                <label>Table 3</label>
                <caption>
                  <title>Isoniazid pharmacokinetics parameter estimates among newly diagnosed sputum smear positive TB patients.</title>
                </caption>
                <alternatives>
                  <graphic id="pone.0141002.t003g" xlink:href="pone.0141002.t003"/>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th rowspan="2" align="center" colspan="1">Parameter description</th>
                        <th colspan="2" align="center" rowspan="1">Typical value</th>
                      </tr>
                      <tr>
                        <th align="center" rowspan="1" colspan="1">Estimate</th>
                        <th align="center" rowspan="1" colspan="1">(90% CI)<xref rid="t003fn003" ref-type="table-fn"><sup>c</sup></xref>
</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Clearance for rapid/intermediate NAT2 acetylators<xref rid="t003fn001" ref-type="table-fn"><sup>a</sup></xref>(L/h)</td>
                        <td align="center" rowspan="1" colspan="1">26.1</td>
                        <td align="center" rowspan="1" colspan="1">(23.6; 29.5)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Clearance for slow NAT2 acetylators<xref rid="t003fn001" ref-type="table-fn"><sup>a</sup></xref> (L/h)</td>
                        <td align="center" rowspan="1" colspan="1">15.5</td>
                        <td align="center" rowspan="1" colspan="1">(14.3; 16.7)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Central volume of distribution<xref rid="t003fn001" ref-type="table-fn"><sup>a</sup></xref> - Vc (L)</td>
                        <td align="center" rowspan="1" colspan="1">48.2</td>
                        <td align="center" rowspan="1" colspan="1">(18.7; 56.4)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Inter-compartmental clearance<xref rid="t003fn001" ref-type="table-fn"><sup>a</sup></xref> Q (L/h)</td>
                        <td align="center" rowspan="1" colspan="1">16.1</td>
                        <td align="center" rowspan="1" colspan="1">(7.5; 61.6)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Peripheral volume<xref rid="t003fn001" ref-type="table-fn"><sup>a</sup></xref> V<sub>p</sub>(L)</td>
                        <td align="center" rowspan="1" colspan="1">16.5</td>
                        <td align="center" rowspan="1" colspan="1">(12.4; 45.4)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Mean transit time âMTTâ (h)</td>
                        <td align="center" rowspan="1" colspan="1">0.924</td>
                        <td align="center" rowspan="1" colspan="1">(0.78; 1.33)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Number of transit compartmentââNNâ</td>
                        <td align="center" rowspan="1" colspan="1">2.73</td>
                        <td align="center" rowspan="1" colspan="1">(1.15; 5.49)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">BioavailabilityââFâ</td>
                        <td align="center" rowspan="1" colspan="1">1 FIXED</td>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Proportional error (%)</td>
                        <td align="center" rowspan="1" colspan="1">13.3</td>
                        <td align="center" rowspan="1" colspan="1">(11.7; 14.4)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Additive error (mg/L)</td>
                        <td align="center" rowspan="1" colspan="1">0.0224 FIXED</td>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Between subject variability of clearance<xref rid="t003fn002" ref-type="table-fn"><sup>b</sup></xref> (%CV)</td>
                        <td align="center" rowspan="1" colspan="1">30.7 [6%]</td>
                        <td align="center" rowspan="1" colspan="1">(24.8; 35.5)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Between occasion variability of mean transit time<xref rid="t003fn002" ref-type="table-fn"><sup>b</sup></xref> (%CV)</td>
                        <td align="center" rowspan="1" colspan="1">37.4 [29%]</td>
                        <td align="center" rowspan="1" colspan="1">(25.8; 41.7)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Between occasion variability of bioavailability<xref rid="t003fn002" ref-type="table-fn"><sup>b</sup></xref> (%CV)</td>
                        <td align="center" rowspan="1" colspan="1">12.8 [79%]</td>
                        <td align="center" rowspan="1" colspan="1">(11.1; 15.7)</td>
                      </tr>
                    </tbody>
                  </table>
                </alternatives>
                <table-wrap-foot>
                  <fn id="t003fn001">
                    <p><sup>a</sup>Allometric scaling was used for CL, Vc, Q, and Vp,so the typical values are reported for the median fat-free mass of the cohort (43 kg)</p>
                  </fn>
                  <fn id="t003fn002">
                    <p><sup>b</sup>The between-subject andâoccasion variability was assumed log-normally distributed and is reported here as approximate %CV. In square brackets, the value of shrinkage.</p>
                  </fn>
                  <fn id="t003fn003">
                    <p><sup>c</sup>The precision of the estimates was obtained with a non-parametric 90% confidence interval based on a 500 sample bootstrap</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <p>For pyrazinamide and ethambutol, only116 PK profiles from 98 patients based on 346 plasma concentrations, were included in the PK modelling. Since many patients had already been switched to the continuation phase of treatment, comprised only of isoniazid and rifampicin, at the time of the second PK visit, the number of analysed patients is lower than for the isoniazid studies (n = 18). No plasma concentrations were BLQ.</p>
              <p>For pyrazinamide, the best model was a one-compartment disposition, first-order elimination, and transit compartment absorption with no separate estimate of absorption rate constants (k<sub>transit</sub> = k<sub>a</sub>). The final parameter estimates are included in <bold><xref rid="pone.0141002.t004" ref-type="table">Table 4</xref>,</bold> while a visual predictive check is shown in <bold><xref rid="pone.0141002.g004" ref-type="fig">Fig 4</xref></bold>. The best size predictor for allometric scaling of clearance was total body weight, while volume of distribution was better scaled with fat-free mass. Pyrazinamide clearance increased with time on treatment: the model estimated 16.3% faster clearance from the data collected after more than 18 days of treatment (-6.96 OFV, p&lt;0.01). This break point was chosen to include all PK profiles from the second PK visit, mostly collected 2 months after treatment initiation, plus two late-comers for the first PK occasion (on days 19 and 26). Other factors including HIV status, nutritional supplementation, age, sex, CD4 count, and weight-adjusted dose were tested in the model, but did not significantly influence pyrazinamide PK. The relationship between these individual values of pyrazinamide exposure and time on TB treatment is shown in <bold><xref rid="pone.0141002.g005" ref-type="fig">Fig 5</xref></bold>. Among the PK profiles obtained in the first 2 weeks of TB treatment, median pyrazinamide AUC<sub>0-24</sub> and C<sub>max</sub> were 413 hÂ·mg/L (IQR: 337; 546) and 37.8 mg/L (IQR: 32.8; 44.5), respectively. For the profiles collected after 2 weeks of TB treatment AUC<sub>0-24</sub> and C<sub>max</sub> decreased to 364 hÂ·mg/L (IQR: 277; 433) and 32.4 mg/L (IQR: 30.9; 37.5), respectively.</p>
              <fig id="pone.0141002.g004" orientation="portrait" position="float">
                <object-id pub-id-type="doi">10.1371/journal.pone.0141002.g004</object-id>
                <label>Fig 4</label>
                <caption>
                  <title>Visual predictive check (VPC) for pyrazinamide concentration versus time, stratified by time on TB treatment.</title>
                  <p>The circles represent the original data, the dashed and solid lines are the 5<sup>th</sup>, 50<sup>th</sup>, and 95<sup>th</sup> percentiles of the original data, while the shaded areas are the corresponding 95% confidence intervals for the same percentiles, as predicted by the model.</p>
                </caption>
                <graphic xlink:href="pone.0141002.g004"/>
              </fig>
              <fig id="pone.0141002.g005" orientation="portrait" position="float">
                <object-id pub-id-type="doi">10.1371/journal.pone.0141002.g005</object-id>
                <label>Fig 5</label>
                <caption>
                  <title>Box and whisker plots showing pyrazinamide exposure vs. time on TB treatment (approximately less or more than 2 weeks).</title>
                  <p>The left panel displays AUC<sub>0-24</sub> and the right panel C<sub>max</sub>. The dots represent individual values. When 2 PK profiles were available in the same stratum, geometric mean was used to summarize the value.</p>
                </caption>
                <graphic xlink:href="pone.0141002.g005"/>
              </fig>
              <table-wrap id="pone.0141002.t004" orientation="portrait" position="float">
                <object-id pub-id-type="doi">10.1371/journal.pone.0141002.t004</object-id>
                <label>Table 4</label>
                <caption>
                  <title>Pyrazinamide pharmacokinetics parameter estimates among newly diagnosed sputum smear positive pulmonary TB patients.</title>
                </caption>
                <alternatives>
                  <graphic id="pone.0141002.t004g" xlink:href="pone.0141002.t004"/>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th rowspan="2" align="center" colspan="1">Parameter description</th>
                        <th colspan="2" align="center" rowspan="1">Typical value</th>
                      </tr>
                      <tr>
                        <th align="center" rowspan="1" colspan="1">Estimate</th>
                        <th align="center" rowspan="1" colspan="1">(90% CI)<xref rid="t004fn004" ref-type="table-fn"><sup>d</sup></xref>
</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Clearance<sup>a</sup>âCL (L/h)</td>
                        <td align="center" rowspan="1" colspan="1">3.32</td>
                        <td align="center" rowspan="1" colspan="1">(3.10; 3.53)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Volume of distribution<xref rid="t004fn001" ref-type="table-fn"><sup>a</sup></xref> âV<sub>d</sub> (L)</td>
                        <td align="center" rowspan="1" colspan="1">40.1</td>
                        <td align="center" rowspan="1" colspan="1">(38.4; 42.1)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Absorption mean transit timeââMTTâ (h)</td>
                        <td align="center" rowspan="1" colspan="1">0.84</td>
                        <td align="center" rowspan="1" colspan="1">(0.42; 1.08)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Number of absorption transit compartmentsâNN</td>
                        <td align="center" rowspan="1" colspan="1">2.6</td>
                        <td align="center" rowspan="1" colspan="1">(0.2; 7.3)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">BioavailabilityâF</td>
                        <td align="center" rowspan="1" colspan="1">1 FIXED</td>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Clearance change after 2 months of treatment<xref rid="t004fn002" ref-type="table-fn"><sup>b</sup></xref> (+%)</td>
                        <td align="center" rowspan="1" colspan="1">16.3</td>
                        <td align="center" rowspan="1" colspan="1">(2.6; 29.2)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Proportional error (%)</td>
                        <td align="center" rowspan="1" colspan="1">7.2</td>
                        <td align="center" rowspan="1" colspan="1">(6.0; 8.1)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Additive error (mg/L)</td>
                        <td align="center" rowspan="1" colspan="1">0.041 FIXED</td>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Between-subject variability in clearance<xref rid="t004fn003" ref-type="table-fn"><sup>c</sup></xref> (%CV)</td>
                        <td align="center" rowspan="1" colspan="1">22.6 [28%]</td>
                        <td align="center" rowspan="1" colspan="1">(11.7; 30.8)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Between-occasion variability in clearance<xref rid="t004fn003" ref-type="table-fn"><sup>c</sup></xref> (%CV)</td>
                        <td align="center" rowspan="1" colspan="1">19.3 [40%]</td>
                        <td align="center" rowspan="1" colspan="1">(2.0; 28.2)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Between-occasion variability in mean transit time<sup>c</sup> (%CV)</td>
                        <td align="center" rowspan="1" colspan="1">46.9 [38%]</td>
                        <td align="center" rowspan="1" colspan="1">(32.3; 89.9)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Between-occasion variability in bioavailability<sup>c</sup> (%CV)</td>
                        <td align="center" rowspan="1" colspan="1">10.1 [39%]</td>
                        <td align="center" rowspan="1" colspan="1">(4.6; 13.2)</td>
                      </tr>
                    </tbody>
                  </table>
                </alternatives>
                <table-wrap-foot>
                  <fn id="t004fn001">
                    <p><sup>a</sup>Allometric scaling was used for clearance (total weight) and volume of distribution (fat-free mass), so the values are reported for the median weight (52 kg) and fat-free mass (43 kg) of the cohort.</p>
                  </fn>
                  <fn id="t004fn002">
                    <p><sup>b</sup>Although nearly all the profiles with increased clearance were collected at ~2 months after TB treatment initiation, the cut-off used in the model was 18 days.</p>
                  </fn>
                  <fn id="t004fn003">
                    <p><sup>c</sup>The between-subject andâoccasion variability was assumed log-normally distributed and is reported here as approximate %CV. In square brackets, the value of shrinkage.</p>
                  </fn>
                  <fn id="t004fn004">
                    <p><sup>d</sup>The precision of the estimates was obtained with a non-parametric 90% confidence interval based on a 500-sample bootstrap.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <p>For ethambutol, the best-fitting model was a two-compartment disposition, with first-order elimination, and transit compartment absorption with no separate estimate of k<sub>a</sub>. The final parameter estimates are shown in <bold><xref rid="pone.0141002.t005" ref-type="table">Table 5</xref></bold>and a visual predictive check is shown in <bold><xref rid="pone.0141002.g006" ref-type="fig">Fig 6</xref></bold>. Although the inclusion of two-compartment disposition kinetics significantly improved the model fit (-30 points OFV), the parameter estimates for the volume of the peripheral compartment (Vp) and the inter-compartmental clearance (Q) proved unstable. To stabilise the model while allowing the inclusion of the two-compartment kinetics, a prior was included [<xref rid="pone.0141002.ref028" ref-type="bibr">28</xref>], based on parameter estimates from a PK model of ethambutol developed on data from a similar population of TB patients [<xref rid="pone.0141002.ref029" ref-type="bibr">29</xref>]. After applying allometric scaling to adjust for differences in body weight amongst the studies, the typical values for the priors of Vp and Q were 420.7 L/h and 64.4 L/h, respectively. The priors were assumed to have a Gaussian distribution around these typical values, and were included in the model imputing a large uncertainty (50% CV) to make them weakly informative. Testing different settings for the prior distributions showed that the estimates of the other parameters in the model were not significantly affected. After the inclusion of the priors, the two-compartment model proved stable and provided a significantly better fit than the one-compartment model, and was used for the analysis. The best predictor for allometric scaling of all clearance and volume parameters was total body weight. Additionally, older age was associated with lower clearance, with every year of age causing a decrease of 1.41% in clearance (-23.4 OFV, p&lt;10 <sup>-5</sup>). No other factors tested in the model, including HIV status, nutritional supplementation, sex, CD4 count, and time on TB treatment, significantly affected the PK. The relationship between the individual values of ethambutol exposure and age is shown in <bold><xref rid="pone.0141002.g007" ref-type="fig">Fig 7</xref></bold>. Median ethambutol AUC<sub>0-24</sub> was 23.6 hÂ·mg/L (IQR: 20.5; 28.9) and C<sub>max</sub> was 2.44 mg/L (IQR: 2.09; 2.86).</p>
              <fig id="pone.0141002.g006" orientation="portrait" position="float">
                <object-id pub-id-type="doi">10.1371/journal.pone.0141002.g006</object-id>
                <label>Fig 6</label>
                <caption>
                  <title>Visual predictive check (VPC) for ethambutol concentration versus time.</title>
                  <p>The circles represent the original data, the dashed and solid lines are the 5<sup>th</sup>, 50<sup>th</sup>, and 95<sup>th</sup> percentiles of the original data, while the shaded areas are the corresponding 95% confidence intervals for the same percentiles, as predicted by the model.</p>
                </caption>
                <graphic xlink:href="pone.0141002.g006"/>
              </fig>
              <fig id="pone.0141002.g007" orientation="portrait" position="float">
                <object-id pub-id-type="doi">10.1371/journal.pone.0141002.g007</object-id>
                <label>Fig 7</label>
                <caption>
                  <title>In the left panels, scatter plots showing ethambutol exposure vs. patient age.</title>
                  <p>In the right small panels, box and whiskers plots summarizing the same values. The top panels refer to AUC<sub>0-24</sub> and the bottom panels to C<sub>max</sub>. For all patients for whom 2 PK profiles were available, geometric mean was used to obtain summary values.</p>
                </caption>
                <graphic xlink:href="pone.0141002.g007"/>
              </fig>
              <table-wrap id="pone.0141002.t005" orientation="portrait" position="float">
                <object-id pub-id-type="doi">10.1371/journal.pone.0141002.t005</object-id>
                <label>Table 5</label>
                <caption>
                  <title>Ethambutol pharmacokinetics parameter estimates among newly diagnosed sputum smear positive pulmonary TB patients.</title>
                </caption>
                <alternatives>
                  <graphic id="pone.0141002.t005g" xlink:href="pone.0141002.t005"/>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th rowspan="2" align="center" colspan="1">Parameter description</th>
                        <th colspan="2" align="center" rowspan="1">Typical value</th>
                      </tr>
                      <tr>
                        <th align="center" rowspan="1" colspan="1">Estimate</th>
                        <th align="center" rowspan="1" colspan="1">(90% CI)<xref rid="t005fn005" ref-type="table-fn"><sup>e</sup></xref>
</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Clearance<xref rid="t005fn001" ref-type="table-fn"><sup>a</sup></xref>
<sup>,</sup>
<xref rid="t005fn002" ref-type="table-fn"><sup>b</sup></xref> âCL (L/h)</td>
                        <td align="center" rowspan="1" colspan="1">40.7</td>
                        <td align="center" rowspan="1" colspan="1">(35.7; 45.2)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Central volume of distribution<xref rid="t005fn001" ref-type="table-fn"><sup>a</sup></xref> - Vc (L)</td>
                        <td align="center" rowspan="1" colspan="1">266</td>
                        <td align="center" rowspan="1" colspan="1">(207; 326)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Inter-compartmental clearance<xref rid="t005fn001" ref-type="table-fn"><sup>a</sup></xref>
<sup>,</sup>
<xref rid="t005fn003" ref-type="table-fn"><sup>c</sup></xref> - Q (L/h)</td>
                        <td align="center" rowspan="1" colspan="1">109</td>
                        <td align="center" rowspan="1" colspan="1">(82; 136)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Peripheral volume of distribution<xref rid="t005fn001" ref-type="table-fn"><sup>a</sup></xref>
<sup>,</sup>
<xref rid="t005fn003" ref-type="table-fn"><sup>c</sup></xref> - Vp (L)</td>
                        <td align="center" rowspan="1" colspan="1">687</td>
                        <td align="center" rowspan="1" colspan="1">(493; 850)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Absorption mean transit timeââMTTâ (h)</td>
                        <td align="center" rowspan="1" colspan="1">2.54</td>
                        <td align="center" rowspan="1" colspan="1">(2.32; 2.78)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Number of absorption transit compartmentsâNN</td>
                        <td align="center" rowspan="1" colspan="1">11.1</td>
                        <td align="center" rowspan="1" colspan="1">(6.0; 30.2)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">BioavailabilityâF</td>
                        <td align="center" rowspan="1" colspan="1">1 FIXED</td>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Effect of age on Clearance (% change per year)</td>
                        <td align="center" rowspan="1" colspan="1">-1.41</td>
                        <td align="center" rowspan="1" colspan="1">(-1.76; -1.09)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Proportional error (%)</td>
                        <td align="center" rowspan="1" colspan="1">22.5</td>
                        <td align="center" rowspan="1" colspan="1">(19.1; 24.5)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Additive error (mg/L)</td>
                        <td align="center" rowspan="1" colspan="1">0.0162 FIXED</td>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Between-subject variability in bioavailability<xref rid="t005fn004" ref-type="table-fn"><sup>d</sup></xref> (%CV)</td>
                        <td align="center" rowspan="1" colspan="1">21.5 [14%]</td>
                        <td align="center" rowspan="1" colspan="1">(15.7; 26.2)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Between-occasion variability in mean transit time<xref rid="t005fn004" ref-type="table-fn"><sup>d</sup></xref> (%CV)</td>
                        <td align="center" rowspan="1" colspan="1">26.1 [14%]</td>
                        <td align="center" rowspan="1" colspan="1">(16.9; 33.7)</td>
                      </tr>
                    </tbody>
                  </table>
                </alternatives>
                <table-wrap-foot>
                  <fn id="t005fn001">
                    <p><sup>a</sup>Allometric scaling was used for CL, Vc, Q, and Vp, so the values are reported for the median weight of the cohort (52 kg).</p>
                  </fn>
                  <fn id="t005fn002">
                    <p><sup>b</sup>CL was affected by age, the typical value reported here refers to the median age in the cohort (35 years)</p>
                  </fn>
                  <fn id="t005fn003">
                    <p><sup>c</sup>Q and Vp were estimated using Gaussian priors with typical values 64.4 L/h and 420.7 L respectively, and 50% uncertainty.</p>
                  </fn>
                  <fn id="t005fn004">
                    <p><sup>d</sup>The between-subject andâoccasion variability was assumed log-normally distributed and is reported here as approximate %CV. In square brackets, the value of shrinkage.</p>
                  </fn>
                  <fn id="t005fn005">
                    <p><sup>e</sup>The precision of the estimates was obtained with a non-parametric 90% confidence interval based on a 500 sample bootstrap</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
            </sec>
            <sec sec-type="conclusions" id="sec012">
              <title>Discussion</title>
              <p>We studied the effect of nutritional supplementation and HIV status on the pharmacokinetics of isoniazid, pyrazinamide, and ethambutol in pulmonary TB patients during the intensive phase of a standard course of TB treatment.</p>
              <p>Malnutrition is a well-known companion to both HIV and TB, and food programs are therefore being launched in many Sub-Saharan regions to alleviate this problem. Nutritional supplementation has previously been reported to improve treatment outcome in both TB and HIV patients [<xref rid="pone.0141002.ref030" ref-type="bibr">30</xref>, <xref rid="pone.0141002.ref031" ref-type="bibr">31</xref>], so our study aimed to investigate if nutritional intervention is affecting the PK exposure of the first-line TB drugs. We recently published the beneficial effect of nutritional supplementation on rifampicin exposure, especially in HIV positive TB patients [<xref rid="pone.0141002.ref020" ref-type="bibr">20</xref>]. In the current study, we found that nutritional supplementation had no effect on isoniazid, pyrazinamide, and ethambutol exposure, and there was no effect of HIV co-infection. The effect of nutritional supplements may depend on the individualâs baseline micronutrients status and only cause an effect in undernourished subjects [<xref rid="pone.0141002.ref032" ref-type="bibr">32</xref>]. In our cohort, baseline BMI was 18.8 (IQR 17.3; 19.9) which classifies most of the participants in the category of underweight; however, we did not assess their micronutrient status.</p>
              <p>We further assessed predictors that potentially could influence the PK, including the NAT2 genotype, age of the patient, and timing of the sampling with respect to treatment initiation. The NAT2 gene product is expressed in the liver and small intestine, constituting an important phase II enzyme responsible for acetylating isoniazid [<xref rid="pone.0141002.ref033" ref-type="bibr">33</xref>]. NAT2 activities may vary due to differences in the NAT2 alleles or haplotypes caused by Single-Nucleotide Polymorphisms (SNPs) [<xref rid="pone.0141002.ref033" ref-type="bibr">33</xref>]. As expected, NAT2 genotype strongly influenced isoniazid pharmacokinetics. Patients categorized as slow NAT2 acetylators had a lower clearance (typical value 15.5 vs. 26.1 L/h) and higher estimated isoniazid exposures (AUC<sub>0-24</sub> of 17.1 vs. 9.89 hÂ·mg/L).compared to rapid or intermediate NAT2 acetylators. The distribution of NAT2 genotypes is comparable to what was found by Sabbagh <italic>et al</italic>. and Matimba <italic>et al</italic>. who reported a high prevalence of slow and intermediate acetylators in African populations, due to the common <italic>NAT2*5</italic>, <italic>*6</italic>, and <italic>*14</italic> polymorphisms [<xref rid="pone.0141002.ref034" ref-type="bibr">34</xref>, <xref rid="pone.0141002.ref035" ref-type="bibr">35</xref>]. Our findings are in line with those reported by Conte <italic>et al</italic>. examining the effects of gender, AIDS, and acetylator status on the steady-state concentrations of orally administered isoniazid in plasma and lungs [<xref rid="pone.0141002.ref036" ref-type="bibr">36</xref>]. Similar findings were reported by Chen <italic>et al</italic>. assessing the influence of NAT2 genotype on the plasma concentration of isoniazid and acetyl-isoniazid in a Chinese population [<xref rid="pone.0141002.ref037" ref-type="bibr">37</xref>]. Pasipanodya <italic>et al</italic>. have compiled these results in a meta-analysis and suggest that this genetic variability is a contributing factor for microbiological treatment failure [<xref rid="pone.0141002.ref009" ref-type="bibr">9</xref>].</p>
              <p>When characterising pyrazinamide PK, we found that clearance increases with time on treatment, an observation also recently reported by Chirehwa <italic>et al</italic>, in South African TB patients co-infected with HIV [<xref rid="pone.0141002.ref038" ref-type="bibr">38</xref>]. They detected an increase of 19% in clearance by day 28 after treatment initiation, which is comparable with our finding of a 16.3% increase. During TB treatment, pyrazinamide is given concomitantly (or even co-formulated) with rifampicin, which is a well-known potent inducer of hepatic and intestinal CYP3A subfamily and many other metabolic pathways via activation of the pregnane X-receptor (PXR) [<xref rid="pone.0141002.ref039" ref-type="bibr">39</xref>]. For this reason, rifampicin exposure results in increasing clearance of many co-administered drugs, and it could be speculated that rifampicin may induce microsomal deamidase or some other pathway, thus enhancing pyrazinamide clearance [<xref rid="pone.0141002.ref038" ref-type="bibr">38</xref>]. On the other hand, the observed increase in clearance could also be the effect of the overall improvement in health conditions of the patients after treatment initiation. The pyrazinamide exposures we observed did not significantly deviate from previous results [<xref rid="pone.0141002.ref040" ref-type="bibr">40</xref>â<xref rid="pone.0141002.ref044" ref-type="bibr">44</xref>]. In the current study, the estimates for median pyrazinamide C<sub>max</sub> and AUC<sub>0-24</sub> were in line with previous reports showing median C<sub>max</sub> levels ranging from 27 to 38 mg/L and AUC<sub>0-24</sub> between 321 and 418 hÂ·mg/L [<xref rid="pone.0141002.ref041" ref-type="bibr">41</xref>â<xref rid="pone.0141002.ref044" ref-type="bibr">44</xref>]. Our results also confirm the reports by Fahimi <italic>et al</italic>. and Tappero <italic>et al</italic>. who showed that the majority of patients achieve pyrazinamide plasma exposures within a range relatively narrower than other TB drugs, due to its efficient absorption [<xref rid="pone.0141002.ref045" ref-type="bibr">45</xref>, <xref rid="pone.0141002.ref046" ref-type="bibr">46</xref>]. Pasipanodya <italic>et al</italic>. recently investigated the TB drug concentration levels that are predictive of TB treatment outcome, and they reported that pyrazinamide peak concentration â¤ 58.3 mg/L was associated with poor 2-month sputum conversion, while AUC<sub>0-24</sub> â¤ 363 hÂ·mg/L was one of the predictors of poor long term outcome [<xref rid="pone.0141002.ref007" ref-type="bibr">7</xref>]. In their analysis, PK exposures were measured at 2 months after treatment initiation. In our cohort, only one PK profile had C<sub>max</sub> above the proposed threshold at around 2 months after treatment initiation. The overall median C<sub>max</sub> was 32.4 mg/L, while the median pyrazinamide AUC<sub>0-24</sub> at around 2 months after treatment initiation was 364 hÂ·mg/L, and a similar value is obtained when adjusting the median AUC<sub>0-24</sub> observed after 1 week to account for the estimated increase in clearance, i.e., multiplying by 1/(1+16.3%). More specifically, we found that 31.6% of this population had pyrazinamide AUC<sub>0-24</sub> â¤ 363 hÂ·mg/L around 1 week and 55.6% at around 2 months after TB treatment initiation. This means that about half of the patients in our cohort achieved exposures below the proposed AUC threshold, and nearly none achieved C<sub>max</sub> above the cut-off. Unfortunately, our study was not powered to assess the long-term effect of drug exposure on treatment outcome.</p>
              <p>Ethambutol plasma concentrations among our study participants were relatively low compared with previous studies [<xref rid="pone.0141002.ref010" ref-type="bibr">10</xref>, <xref rid="pone.0141002.ref040" ref-type="bibr">40</xref>â<xref rid="pone.0141002.ref042" ref-type="bibr">42</xref>, <xref rid="pone.0141002.ref044" ref-type="bibr">44</xref>], reporting median C<sub>max</sub> ranging from 2.7 to 4.8 mg/L and median AUC<sub>0-24</sub> between 20 and 47 hÂ·mg/L. In our cohort, median ethambutol C<sub>max</sub> was 2.44 mg/L and AUC<sub>0-24</sub> was 23.6 hÂ·mg/L, values similar to those reported by Tappero <italic>et al</italic>. and Um <italic>et al</italic>. [<xref rid="pone.0141002.ref046" ref-type="bibr">46</xref>, <xref rid="pone.0141002.ref047" ref-type="bibr">47</xref>]. Ethambutol pharmacokinetics has been previously associated with many factors including malnutrition, HIV infection, age, and sex [<xref rid="pone.0141002.ref012" ref-type="bibr">12</xref>, <xref rid="pone.0141002.ref042" ref-type="bibr">42</xref>, <xref rid="pone.0141002.ref048" ref-type="bibr">48</xref>â<xref rid="pone.0141002.ref050" ref-type="bibr">50</xref>]. In our cohort, age was found to affect ethambutol clearance, with increasing age leading to lower clearance at a decrease rate of 1.41% per year. A relationship between age and anti-TB drug plasma levels has been previously reported in a study in South African patients [<xref rid="pone.0141002.ref012" ref-type="bibr">12</xref>], where it was suggested that older patients have higher levels of ethambutol and isoniazid because of the functional decrease of metabolic pathways and reduced renal clearance capacity. HIV infection was not found to affect ethambutol plasma concentration in this population, in contrast to studies by Zhu <italic>et al</italic>. [<xref rid="pone.0141002.ref051" ref-type="bibr">51</xref>] and Jonsson <italic>et al</italic>. [<xref rid="pone.0141002.ref010" ref-type="bibr">10</xref>], who both reported that HIV infection was associated with a reduction in ethambutol concentrations.</p>
              <sec id="sec013">
                <title>Limitations and strengths</title>
                <p>The number of PK samples collected at each visit was small, limiting the characterization of the pharmacokinetic curve, as well as the precision of the individual estimates of exposure, especially C<sub>max</sub>. This was a compromise accepted in the study design to limit the time patients had to spend at the clinic during PK sampling, as the patients involved were treated as outpatients. The data was interpreted with nonlinear mixed-effects modelling, which appropriately handles sparse sampling and supports the robustness of our findings.</p>
                <p>Another limitation of the study is represented by the few PK profiles of pyrazinamide and ethambutol available from the second visit (only 18 out of those that came back for the second evaluation), since a majority of the patients had already been switched to the continuation phase not including pyrazinamide and ethambutol. This missingness of the data reduced the sample size for the investigation of the effect of the time on treatment, but nonlinear mixed-effects modelling is known to handle these kinds of scenarios well. Moreover, the two cohorts (patients in continuation vs intensive phase at PK visit 2) had similar demographic characteristics and similar proportions of HIV infection and subjects randomised to supplementation (data not shown).</p>
                <p>This study was initiated and conducted before clear policies regarding the timing of ART to HIV co-infected TB patients were established. Therefore pharmacologic interaction with various ARTs is not an issue in this study.</p>
              </sec>
            </sec>
            <sec sec-type="conclusions" id="sec014">
              <title>Conclusions</title>
              <p>In summary, we reported the pharmacokinetics of isoniazid, pyrazinamide, and ethambutol in a cohort of Tanzanian TB patients. We found that nutritional supplements with energy-protein plus micronutrients given to TB patients during the intensive phase of a conventional TB regimen have no effect on the exposure of isoniazid, pyrazinamide, or ethambutol. HIV status did not influence this result. Intermediate and rapid NAT2 genotypes were associated with lower isoniazid exposure. Pyrazinamide clearance increased with time on treatment, which was associated with lower serum pyrazinamide levels at the end of intensive phase of TB treatment. Ethambutol plasma concentrations were relatively low in our cohort of Tanzanian patients compared with previous studies, and older age was associated with lower clearance of ethambutol.</p>
            </sec>
            <sec sec-type="supplementary-material" id="sec015">
              <title>Supporting Information</title>
              <supplementary-material content-type="local-data" id="pone.0141002.s001">
                <label>S1 Protocol</label>
                <caption>
                  <title>Supplementary PDF file with the study protocol.</title>
                  <p>(DOC)</p>
                </caption>
                <media xlink:href="pone.0141002.s001.doc">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack>
              <p>The authors would like to thank the health staff and study participants involved in the study. Special thanks go to Oswald Kaswamila, Lucy Magawa, and David Madili of the National Institute for Medical Research in Mwanza for excellent laboratory and clinical work assistance.The authors also acknowledge the contribution of Wynand Smythe at the University of Cape Town, who provided the prior values to support the PK model of ethambutol. The University of Cape Town analytical lab that performed that drug quantification assay was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number UM1 AI106701. The Division of Clinical Pharmacology at the University of Cape Town acknowledge Novartis Pharma for their support of the development of pharmacometrics skills in Africa.</p>
            </ack>
            <ref-list>
              <title>References</title>
              <ref id="pone.0141002.ref001">
                <label>1</label>
                <mixed-citation publication-type="journal"><name><surname>Wada</surname><given-names>M</given-names></name>, <name><surname>Yoshiyama</surname><given-names>T</given-names></name>, <name><surname>Ogata</surname><given-names>H</given-names></name>, <name><surname>Ito</surname><given-names>K</given-names></name>, <name><surname>Mizutani</surname><given-names>S</given-names></name>, <name><surname>Sugita</surname><given-names>H</given-names></name>. [<article-title>Six-months chemotherapy (2HRZS or E/4HRE) of new cases of pulmonary tuberculosisâsix year experiences on its effectiveness, toxicity, and acceptability</article-title>]. <source>Kekkaku</source>. <year>1999</year>;<volume>74</volume>(<issue>4</issue>):<fpage>353</fpage>â<lpage>60</lpage>. Epub 1999/06/04. .<?supplied-pmid 10355221?><pub-id pub-id-type="pmid">10355221</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0141002.ref002">
                <label>2</label>
                <mixed-citation publication-type="journal"><article-title>Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society</article-title>. <source>Monaldi Arch Chest Dis</source>. <volume>49</volume>(<issue>4</issue>):<fpage>327</fpage>â<lpage>45</lpage>. Epub 1994/09/01. .<?supplied-pmid 8000420?><pub-id pub-id-type="pmid">8000420</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0141002.ref003">
                <label>3</label>
                <mixed-citation publication-type="journal"><name><surname>Fattorini</surname><given-names>L</given-names></name>, <name><surname>Piccaro</surname><given-names>G</given-names></name>, <name><surname>Mustazzolu</surname><given-names>A</given-names></name>, <name><surname>Giannoni</surname><given-names>F</given-names></name>. <article-title>Targeting Dormant Bacilli to Fight Tuberculosis</article-title>. <source>Mediterr J Hematol Infect Dis</source>. <year>2013</year>;<volume>5</volume>(<issue>1</issue>):<fpage>e2013072</fpage> Epub 2013/12/24. <pub-id pub-id-type="doi">10.4084/mjhid.2013.072</pub-id>
<?supplied-pmid 24363887?><pub-id pub-id-type="pmid">24363887</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0141002.ref004">
                <label>4</label>
                <mixed-citation publication-type="book"><collab>World Health Organization</collab>. <chapter-title>Global tuberculosis report 2013</chapter-title><publisher-loc>Geneva, Switzerland</publisher-loc>: <publisher-name>World Health Organization</publisher-name>; <year>2013</year>.</mixed-citation>
              </ref>
              <ref id="pone.0141002.ref005">
                <label>5</label>
                <mixed-citation publication-type="other">Ministry of Health and Social welfare. Manual of the national tuberculosis and leprosy programme in Tanzania Dar es Salaam: 2013 [cited 2014 30 November]. Sixth:[Available from: <ext-link ext-link-type="uri" xlink:href="http://ntlp.go.tz/index.php?option=com_phocadownload&amp;view">ntlp.go.tz/index.php?option=com_phocadownload&amp;view</ext-link>â¦</mixed-citation>
              </ref>
              <ref id="pone.0141002.ref006">
                <label>6</label>
                <mixed-citation publication-type="journal"><name><surname>Peloquin</surname><given-names>CA</given-names></name>. <article-title>Therapeutic drug monitoring in the treatment of tuberculosis</article-title>. <source>Drugs</source>. <year>2002</year>;<volume>62</volume>(<issue>15</issue>):<fpage>2169</fpage>â<lpage>83</lpage>. Epub 2002/10/17. .<?supplied-pmid 12381217?><pub-id pub-id-type="pmid">12381217</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0141002.ref007">
                <label>7</label>
                <mixed-citation publication-type="journal"><name><surname>Pasipanodya</surname><given-names>JG</given-names></name>, <name><surname>McIlleron</surname><given-names>H</given-names></name>, <name><surname>Burger</surname><given-names>A</given-names></name>, <name><surname>Wash</surname><given-names>PA</given-names></name>, <name><surname>Smith</surname><given-names>P</given-names></name>, <name><surname>Gumbo</surname><given-names>T</given-names></name>. <article-title>Serum drug concentrations predictive of pulmonary tuberculosis outcomes</article-title>. <source>J Infect Dis</source>. <year>2013</year>;<volume>208</volume>(<issue>9</issue>):<fpage>1464</fpage>â<lpage>73</lpage>. Epub 2013/08/01. <pub-id pub-id-type="doi">10.1093/infdis/jit352</pub-id>
<?supplied-pmid 23901086?><pub-id pub-id-type="pmid">23901086</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0141002.ref008">
                <label>8</label>
                <mixed-citation publication-type="journal"><name><surname>Srivastava</surname><given-names>S</given-names></name>, <name><surname>Pasipanodya</surname><given-names>JG</given-names></name>, <name><surname>Meek</surname><given-names>C</given-names></name>, <name><surname>Leff</surname><given-names>R</given-names></name>, <name><surname>Gumbo</surname><given-names>T</given-names></name>. <article-title>Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability</article-title>. <source>J Infect Dis</source>. <year>2011</year>;<volume>204</volume>(<issue>12</issue>):<fpage>1951</fpage>â<lpage>9</lpage>. Epub 2011/10/25. <pub-id pub-id-type="doi">10.1093/infdis/jir658</pub-id>
<?supplied-pmid 22021624?><pub-id pub-id-type="pmid">22021624</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0141002.ref009">
                <label>9</label>
                <mixed-citation publication-type="journal"><name><surname>Pasipanodya</surname><given-names>JG</given-names></name>, <name><surname>Srivastava</surname><given-names>S</given-names></name>, <name><surname>Gumbo</surname><given-names>T</given-names></name>. <article-title>Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy</article-title>. <source>Clin Infect Dis</source>. <year>2012</year>;<volume>55</volume>(<issue>2</issue>):<fpage>169</fpage>â<lpage>77</lpage>. Epub 2012/04/03. <pub-id pub-id-type="doi">10.1093/cid/cis353</pub-id>
<?supplied-pmid 22467670?><pub-id pub-id-type="pmid">22467670</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0141002.ref010">
                <label>10</label>
                <mixed-citation publication-type="journal"><name><surname>Jonsson</surname><given-names>S</given-names></name>, <name><surname>Davidse</surname><given-names>A</given-names></name>, <name><surname>Wilkins</surname><given-names>J</given-names></name>, <name><surname>Van der Walt</surname><given-names>JS</given-names></name>, <name><surname>Simonsson</surname><given-names>US</given-names></name>, <name><surname>Karlsson</surname><given-names>MO</given-names></name>, <etal>et al</etal><article-title>Population pharmacokinetics of ethambutol in South African tuberculosis patients</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2011</year>;<volume>55</volume>(<issue>9</issue>):<fpage>4230</fpage>â<lpage>7</lpage>. Epub 2011/06/22. <pub-id pub-id-type="doi">10.1128/aac.00274-11</pub-id>
<?supplied-pmid 21690284?><pub-id pub-id-type="pmid">21690284</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0141002.ref011">
                <label>11</label>
                <mixed-citation publication-type="journal"><name><surname>Wilkins</surname><given-names>JJ</given-names></name>, <name><surname>Langdon</surname><given-names>G</given-names></name>, <name><surname>McIlleron</surname><given-names>H</given-names></name>, <name><surname>Pillai</surname><given-names>GC</given-names></name>, <name><surname>Smith</surname><given-names>PJ</given-names></name>, <name><surname>Simonsson</surname><given-names>US</given-names></name>. <article-title>Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients</article-title>. <source>Eur J Clin Pharmacol</source>. <year>2006</year>;<volume>62</volume>(<issue>9</issue>):<fpage>727</fpage>â<lpage>35</lpage>. Epub 2006/05/11. <pub-id pub-id-type="doi">10.1007/s00228-006-0141-z</pub-id>
.<?supplied-pmid 16685561?><pub-id pub-id-type="pmid">16685561</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0141002.ref012">
                <label>12</label>
                <mixed-citation publication-type="journal"><name><surname>McIlleron</surname><given-names>H</given-names></name>, <name><surname>Wash</surname><given-names>P</given-names></name>, <name><surname>Burger</surname><given-names>A</given-names></name>, <name><surname>Norman</surname><given-names>J</given-names></name>, <name><surname>Folb</surname><given-names>PI</given-names></name>, <name><surname>Smith</surname><given-names>P</given-names></name>. <article-title>Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2006</year>;<volume>50</volume>(<issue>4</issue>):<fpage>1170</fpage>â<lpage>7</lpage>. Epub 2006/03/30. <pub-id pub-id-type="doi">10.1128/aac.50.4.1170-1177.2006</pub-id>
<?supplied-pmid 16569826?><pub-id pub-id-type="pmid">16569826</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0141002.ref013">
                <label>13</label>
                <mixed-citation publication-type="journal"><name><surname>Chideya</surname><given-names>S</given-names></name>, <name><surname>Winston</surname><given-names>CA</given-names></name>, <name><surname>Peloquin</surname><given-names>CA</given-names></name>, <name><surname>Bradford</surname><given-names>WZ</given-names></name>, <name><surname>Hopewell</surname><given-names>PC</given-names></name>, <name><surname>Wells</surname><given-names>CD</given-names></name>, <etal>et al</etal><article-title>Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana</article-title>. <source>Clin Infect Dis</source>. <year>2009</year>;<volume>48</volume>(<issue>12</issue>):<fpage>1685</fpage>â<lpage>94</lpage>. Epub 2009/05/13. <pub-id pub-id-type="doi">10.1086/599040</pub-id>
<?supplied-pmid 19432554?><pub-id pub-id-type="pmid">19432554</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0141002.ref014">
                <label>14</label>
                <mixed-citation publication-type="journal"><name><surname>Graham</surname><given-names>SM</given-names></name>, <name><surname>Bell</surname><given-names>DJ</given-names></name>, <name><surname>Nyirongo</surname><given-names>S</given-names></name>, <name><surname>Hartkoorn</surname><given-names>R</given-names></name>, <name><surname>Ward</surname><given-names>SA</given-names></name>, <name><surname>Molyneux</surname><given-names>EM</given-names></name>. <article-title>Low levels of pyrazinamide and ethambutol in children with tuberculosis and impact of age, nutritional status, and human immunodeficiency virus infection</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2006</year>;<volume>50</volume>(<issue>2</issue>):<fpage>407</fpage>â<lpage>13</lpage>. Epub 2006/01/27. <pub-id pub-id-type="doi">10.1128/aac.50.2.407-413.2006</pub-id>
<?supplied-pmid 16436690?><pub-id pub-id-type="pmid">16436690</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0141002.ref015">
                <label>15</label>
                <mixed-citation publication-type="journal"><name><surname>Perlman</surname><given-names>DC</given-names></name>, <name><surname>Segal</surname><given-names>Y</given-names></name>, <name><surname>Rosenkranz</surname><given-names>S</given-names></name>, <name><surname>Rainey</surname><given-names>PM</given-names></name>, <name><surname>Remmel</surname><given-names>RP</given-names></name>, <name><surname>Salomon</surname><given-names>N</given-names></name>, <etal>et al</etal><article-title>The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis</article-title>. <source>Clin Infect Dis</source>. <year>2005</year>;<volume>41</volume>(<issue>11</issue>):<fpage>1638</fpage>â<lpage>47</lpage>. Epub 2005/11/04. <pub-id pub-id-type="doi">10.1086/498024</pub-id>
.<?supplied-pmid 16267738?><pub-id pub-id-type="pmid">16267738</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0141002.ref016">
                <label>16</label>
                <mixed-citation publication-type="journal"><name><surname>Gurumurthy</surname><given-names>P</given-names></name>, <name><surname>Ramachandran</surname><given-names>G</given-names></name>, <name><surname>Hemanth</surname><given-names>Kumar AK</given-names></name>, <name><surname>Rajasekaran</surname><given-names>S</given-names></name>, <name><surname>Padmapriyadarsini</surname><given-names>C</given-names></name>, <name><surname>Swaminathan</surname><given-names>S</given-names></name>, <etal>et al</etal><article-title>Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis</article-title>. <source>Clin Infect Dis</source>. <year>2004</year>;<volume>38</volume>(<issue>2</issue>):<fpage>280</fpage>â<lpage>3</lpage>. Epub 2003/12/31. <pub-id pub-id-type="doi">10.1086/380795</pub-id>
.<?supplied-pmid 14699462?><pub-id pub-id-type="pmid">14699462</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0141002.ref017">
                <label>17</label>
                <mixed-citation publication-type="journal"><name><surname>Singh</surname><given-names>N</given-names></name>, <name><surname>Dubey</surname><given-names>S</given-names></name>, <name><surname>Chinnaraj</surname><given-names>S</given-names></name>, <name><surname>Golani</surname><given-names>A</given-names></name>, <name><surname>Maitra</surname><given-names>A</given-names></name>. <article-title>Study of NAT2 gene polymorphisms in an Indian population: association with plasma isoniazid concentration in a cohort of tuberculosis patients</article-title>. <source>Mol Diagn Ther</source>. <year>2009</year>;<volume>13</volume>(<issue>1</issue>):<fpage>49</fpage>â<lpage>58</lpage>. Epub 2009/04/09. <pub-id pub-id-type="doi">10.2165/01250444-200913010-00007</pub-id>
.<?supplied-pmid 19351215?><pub-id pub-id-type="pmid">19351215</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0141002.ref018">
                <label>18</label>
                <mixed-citation publication-type="journal"><name><surname>Oshikoya</surname><given-names>KA</given-names></name>, <name><surname>Sammons</surname><given-names>HM</given-names></name>, <name><surname>Choonara</surname><given-names>I</given-names></name>. <article-title>A systematic review of pharmacokinetics studies in children with protein-energy malnutrition</article-title>. <source>Eur J Clin Pharmacol</source>. <year>2010</year>;<volume>66</volume>(<issue>10</issue>):<fpage>1025</fpage>â<lpage>35</lpage>. Epub 2010/06/17. <pub-id pub-id-type="doi">10.1007/s00228-010-0851-0</pub-id>
.<?supplied-pmid 20552179?><pub-id pub-id-type="pmid">20552179</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0141002.ref019">
                <label>19</label>
                <mixed-citation publication-type="journal"><name><surname>Buchanan</surname><given-names>N</given-names></name>, <name><surname>Eyberg</surname><given-names>C</given-names></name>, <name><surname>Davis</surname><given-names>MD</given-names></name>. <article-title>Isoniazid pharmacokinetics in kwashiorkor</article-title>. <source>S Afr Med J</source>. <year>1979</year>;<volume>56</volume>(<issue>8</issue>):<fpage>299</fpage>â<lpage>300</lpage>. Epub 1979/08/25. .<?supplied-pmid 550491?><pub-id pub-id-type="pmid">550491</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0141002.ref020">
                <label>20</label>
                <mixed-citation publication-type="journal"><name><surname>Jeremiah</surname><given-names>K</given-names></name>, <name><surname>Denti</surname><given-names>P</given-names></name>, <name><surname>Chigutsa</surname><given-names>E</given-names></name>, <name><surname>Faurholt-Jepsen</surname><given-names>D</given-names></name>, <name><surname>PrayGod</surname><given-names>G</given-names></name>, <name><surname>Range</surname><given-names>N</given-names></name>, <etal>et al</etal><article-title>Nutritional supplementation increases rifampin exposure among tuberculosis patients coinfected with HIV</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2014</year>;<volume>58</volume>(<issue>6</issue>):<fpage>3468</fpage>â<lpage>74</lpage>. Epub 2014/04/09. <pub-id pub-id-type="doi">10.1128/aac.02307-13</pub-id>
<?supplied-pmid 24709267?><pub-id pub-id-type="pmid">24709267</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0141002.ref021">
                <label>21</label>
                <mixed-citation publication-type="book"><collab>NACP</collab>. <source>National AIDS Control Programme (NACP) National Guidelines For the Management of HIV and AIDS</source>, <publisher-name>Government of Tanzania</publisher-name><year>2009</year>.</mixed-citation>
              </ref>
              <ref id="pone.0141002.ref022">
                <label>22</label>
                <mixed-citation publication-type="book"><name><surname>Beal</surname><given-names>S</given-names></name>, <name><surname>Sheiner</surname><given-names>L.</given-names></name>, <name><surname>Boeckmann</surname><given-names>A.</given-names></name>, &amp; <name><surname>Bauer</surname><given-names>R.</given-names></name> (<chapter-title>NONMEM users guides (1989â2009</chapter-title>). <publisher-loc>Ellicott City, MD, USA</publisher-loc>,: <publisher-name>ICON Development Solution</publisher-name>; <year>2009</year>.</mixed-citation>
              </ref>
              <ref id="pone.0141002.ref023">
                <label>23</label>
                <mixed-citation publication-type="journal"><name><surname>Keizer</surname><given-names>RJ</given-names></name>, <name><surname>Karlsson</surname><given-names>MO</given-names></name>, <name><surname>Hooker</surname><given-names>A</given-names></name>. <article-title>Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose</article-title>. <source>CPT: pharmacometrics &amp; systems pharmacology</source>. <year>2013</year>;<volume>2</volume>:<fpage>e50</fpage> Epub 2013/07/10. <pub-id pub-id-type="doi">10.1038/psp.2013.24</pub-id>
<?supplied-pmid 23836189?><pub-id pub-id-type="pmid">23836189</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0141002.ref024">
                <label>24</label>
                <mixed-citation publication-type="journal"><name><surname>Savic</surname><given-names>RM</given-names></name>, <name><surname>Jonker</surname><given-names>DM</given-names></name>, <name><surname>Kerbusch</surname><given-names>T</given-names></name>, <name><surname>Karlsson</surname><given-names>MO</given-names></name>. <article-title>Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies</article-title>. <source>J Pharmacokinet Pharmacodyn</source>. <year>2007</year>;<volume>34</volume>(<issue>5</issue>):<fpage>711</fpage>â<lpage>26</lpage>. Epub 2007/07/27. <pub-id pub-id-type="doi">10.1007/s10928-007-9066-0</pub-id>
.<?supplied-pmid 17653836?><pub-id pub-id-type="pmid">17653836</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0141002.ref025">
                <label>25</label>
                <mixed-citation publication-type="journal"><name><surname>Anderson</surname><given-names>BJ</given-names></name>, <name><surname>Holford</surname><given-names>NH</given-names></name>. <article-title>Mechanism-based concepts of size and maturity in pharmacokinetics</article-title>. <source>Annu Rev Pharmacol Toxicol</source>. <year>2008</year>;<volume>48</volume>:<fpage>303</fpage>â<lpage>32</lpage>. Epub 2007/10/05. <pub-id pub-id-type="doi">10.1146/annurev.pharmtox.48.113006.094708</pub-id>
.<?supplied-pmid 17914927?><pub-id pub-id-type="pmid">17914927</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0141002.ref026">
                <label>26</label>
                <mixed-citation publication-type="journal"><name><surname>Savic</surname><given-names>RM</given-names></name>, <name><surname>Karlsson</surname><given-names>MO</given-names></name>. <article-title>Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions</article-title>. <source>The AAPS journal</source>. <year>2009</year>;<volume>11</volume>(<issue>3</issue>):<fpage>558</fpage>â<lpage>69</lpage>. Epub 2009/08/04. <pub-id pub-id-type="doi">10.1208/s12248-009-9133-0</pub-id>
<?supplied-pmid 19649712?><pub-id pub-id-type="pmid">19649712</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0141002.ref027">
                <label>27</label>
                <mixed-citation publication-type="journal"><name><surname>Keizer</surname><given-names>RJ</given-names></name>, <name><surname>Zandvliet</surname><given-names>AS</given-names></name>, <name><surname>Beijnen</surname><given-names>JH</given-names></name>, <name><surname>Schellens</surname><given-names>JH</given-names></name>, <name><surname>Huitema</surname><given-names>AD</given-names></name>. <article-title>Performance of methods for handling missing categorical covariate data in population pharmacokinetic analyses</article-title>. <source>The AAPS journal</source>. <year>2012</year>;<volume>14</volume>(<issue>3</issue>):<fpage>601</fpage>â<lpage>11</lpage>. Epub 2012/06/01. <pub-id pub-id-type="doi">10.1208/s12248-012-9373-2</pub-id>
<?supplied-pmid 22648902?><pub-id pub-id-type="pmid">22648902</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0141002.ref028">
                <label>28</label>
                <mixed-citation publication-type="journal"><name><surname>Gisleskog</surname><given-names>PO</given-names></name>, <name><surname>Karlsson</surname><given-names>MO</given-names></name>, <name><surname>Beal</surname><given-names>SL</given-names></name>. <article-title>Use of prior information to stabilize a population data analysis</article-title>. <source>J Pharmacokinet Pharmacodyn</source>. <year>2002</year>;<volume>29</volume>(<issue>5â6</issue>):<fpage>473</fpage>â<lpage>505</lpage>. Epub 2003/06/11. .<?supplied-pmid 12795242?><pub-id pub-id-type="pmid">12795242</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0141002.ref029">
                <label>29</label>
                <mixed-citation publication-type="journal"><name><surname>Merle</surname><given-names>CS</given-names></name>, <name><surname>Fielding</surname><given-names>K</given-names></name>, <name><surname>Sow</surname><given-names>OB</given-names></name>, <name><surname>Gninafon</surname><given-names>M</given-names></name>, <name><surname>Lo</surname><given-names>MB</given-names></name>, <name><surname>Mthiyane</surname><given-names>T</given-names></name>, <etal>et al</etal><article-title>A four-month gatifloxacin-containing regimen for treating tuberculosis</article-title>. <source>N Engl J Med</source>. <year>2014</year>;<volume>371</volume>(<issue>17</issue>):<fpage>1588</fpage>â<lpage>98</lpage>. Epub 2014/10/23. <pub-id pub-id-type="doi">10.1056/NEJMoa1315817</pub-id>
.<?supplied-pmid 25337748?><pub-id pub-id-type="pmid">25337748</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0141002.ref030">
                <label>30</label>
                <mixed-citation publication-type="journal"><name><surname>Karyadi</surname><given-names>E</given-names></name>, <name><surname>West</surname><given-names>CE</given-names></name>, <name><surname>Schultink</surname><given-names>W</given-names></name>, <name><surname>Nelwan</surname><given-names>RH</given-names></name>, <name><surname>Gross</surname><given-names>R</given-names></name>, <name><surname>Amin</surname><given-names>Z</given-names></name>, <etal>et al</etal><article-title>A double-blind, placebo-controlled study of vitamin A and zinc supplementation in persons with tuberculosis in Indonesia: effects on clinical response and nutritional status</article-title>. <source>Am J Clin Nutr</source>. <year>2002</year>;<volume>75</volume>(<issue>4</issue>):<fpage>720</fpage>â<lpage>7</lpage>. Epub 2002/03/28. .<?supplied-pmid 11916759?><pub-id pub-id-type="pmid">11916759</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0141002.ref031">
                <label>31</label>
                <mixed-citation publication-type="journal"><name><surname>Ramakrishnan</surname><given-names>CV</given-names></name>, <name><surname>Rajendran</surname><given-names>K</given-names></name>, <name><surname>Jacob</surname><given-names>PG</given-names></name>, <name><surname>Fox</surname><given-names>W</given-names></name>, <name><surname>Radhakrishna</surname><given-names>S</given-names></name>. <article-title>The role of diet in the treatment of pulmonary tuberculosis. An evaluation in a controlled chemotherapy study in home and sanatorium patients in South India</article-title>. <source>Bull World Health Organ</source>. <year>1961</year>;<volume>25</volume>:<fpage>339</fpage>â<lpage>59</lpage>. Epub 1961/01/01. <?supplied-pmid 14490066?><pub-id pub-id-type="pmid">14490066</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0141002.ref032">
                <label>32</label>
                <mixed-citation publication-type="journal"><name><surname>Friis</surname><given-names>H</given-names></name>. <article-title>Micronutrient interventions and HIV infection: a review of current evidence</article-title>. <source>Trop Med Int Health</source>. <year>2006</year>;<volume>11</volume>(<issue>12</issue>):<fpage>1849</fpage>â<lpage>57</lpage>. Epub 2006/12/21. <pub-id pub-id-type="doi">10.1111/j.1365-3156.2006.01740.x</pub-id>
.<?supplied-pmid 17176350?><pub-id pub-id-type="pmid">17176350</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0141002.ref033">
                <label>33</label>
                <mixed-citation publication-type="journal"><name><surname>Tilak</surname><given-names>AV</given-names></name>, <name><surname>Iyer</surname><given-names>SN</given-names></name>, <name><surname>Mukherjee</surname><given-names>MS</given-names></name>, <name><surname>Singhal</surname><given-names>RS</given-names></name>, <name><surname>Lele</surname><given-names>SS</given-names></name>. <article-title>Full-gene-sequencing analysis of N-acetyltransferase-2 in an adult Indian population</article-title>. <source>Genetic testing and molecular biomarkers</source>. <year>2013</year>;<volume>17</volume>(<issue>3</issue>):<fpage>188</fpage>â<lpage>94</lpage>. Epub 2012/12/12. <pub-id pub-id-type="doi">10.1089/gtmb.2012.0258</pub-id>
.<?supplied-pmid 23216273?><pub-id pub-id-type="pmid">23216273</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0141002.ref034">
                <label>34</label>
                <mixed-citation publication-type="journal"><name><surname>Matimba</surname><given-names>A</given-names></name>, <name><surname>Del-Favero</surname><given-names>J</given-names></name>, <name><surname>Van Broeckhoven</surname><given-names>C</given-names></name>, <name><surname>Masimirembwa</surname><given-names>C</given-names></name>. <article-title>Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects</article-title>. <source>Human genomics</source>. <year>2009</year>;<volume>3</volume>(<issue>2</issue>):<fpage>169</fpage>â<lpage>90</lpage>. Epub 2009/01/24. <?supplied-pmid 19164093?><pub-id pub-id-type="pmid">19164093</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0141002.ref035">
                <label>35</label>
                <mixed-citation publication-type="journal"><name><surname>Sabbagh</surname><given-names>A</given-names></name>, <name><surname>Langaney</surname><given-names>A</given-names></name>, <name><surname>Darlu</surname><given-names>P</given-names></name>, <name><surname>Gerard</surname><given-names>N</given-names></name>, <name><surname>Krishnamoorthy</surname><given-names>R</given-names></name>, <name><surname>Poloni</surname><given-names>ES</given-names></name>. <article-title>Worldwide distribution of NAT2 diversity: implications for NAT2 evolutionary history</article-title>. <source>BMC Genet</source>. <year>2008</year>;<volume>9</volume>:<fpage>21</fpage> Epub 2008/02/29. <pub-id pub-id-type="doi">10.1186/1471-2156-9-21</pub-id>
<?supplied-pmid 18304320?><pub-id pub-id-type="pmid">18304320</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0141002.ref036">
                <label>36</label>
                <mixed-citation publication-type="journal"><name><surname>Conte</surname><given-names>JE</given-names><suffix>Jr.</suffix></name>, <name><surname>Golden</surname><given-names>JA</given-names></name>, <name><surname>McQuitty</surname><given-names>M</given-names></name>, <name><surname>Kipps</surname><given-names>J</given-names></name>, <name><surname>Duncan</surname><given-names>S</given-names></name>, <name><surname>McKenna</surname><given-names>E</given-names></name>, <etal>et al</etal><article-title>Effects of gender, AIDS, and acetylator status on intrapulmonary concentrations of isoniazid</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2002</year>;<volume>46</volume>(<issue>8</issue>):<fpage>2358</fpage>â<lpage>64</lpage>. Epub 2002/07/18. <?supplied-pmid 12121905?><pub-id pub-id-type="pmid">12121905</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0141002.ref037">
                <label>37</label>
                <mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>B</given-names></name>, <name><surname>Li</surname><given-names>JH</given-names></name>, <name><surname>Xu</surname><given-names>YM</given-names></name>, <name><surname>Wang</surname><given-names>J</given-names></name>, <name><surname>Cao</surname><given-names>XM</given-names></name>. <article-title>The influence of NAT2 genotypes on the plasma concentration of isoniazid and acetylisoniazid in Chinese pulmonary tuberculosis patients</article-title>. <source>Clin Chim Acta</source>. <year>2006</year>;<volume>365</volume>(<issue>1â2</issue>):<fpage>104</fpage>â<lpage>8</lpage>. Epub 2005/09/27. <pub-id pub-id-type="doi">10.1016/j.cca.2005.08.012</pub-id>
.<?supplied-pmid 16182272?><pub-id pub-id-type="pmid">16182272</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0141002.ref038">
                <label>38</label>
                <mixed-citation publication-type="other">Chirehwa MR, R. Mthiyane, T. Onyebujoh, P. Smith, P. McIlleron, H. &amp; Denti,. Population pharmacokinetics of Pyrazinamide among HIV/TB co-infected patients at different levels of immunosuppression in South Africa. In World Congress of Pharmacology. 2014:(p. Poster 265). Cape Town, South Africa.</mixed-citation>
              </ref>
              <ref id="pone.0141002.ref039">
                <label>39</label>
                <mixed-citation publication-type="journal"><name><surname>Niemi</surname><given-names>M</given-names></name>, <name><surname>Backman</surname><given-names>JT</given-names></name>, <name><surname>Fromm</surname><given-names>MF</given-names></name>, <name><surname>Neuvonen</surname><given-names>PJ</given-names></name>, <name><surname>Kivisto</surname><given-names>KT</given-names></name>. <article-title>Pharmacokinetic interactions with rifampicin: clinical relevance</article-title>. <source>Clin Pharmacokinet</source>. <year>2003</year>;<volume>42</volume>(<issue>9</issue>):<fpage>819</fpage>â<lpage>50</lpage>. Epub 2003/07/29. <pub-id pub-id-type="doi">10.2165/00003088-200342090-00003</pub-id>
.<?supplied-pmid 12882588?><pub-id pub-id-type="pmid">12882588</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0141002.ref040">
                <label>40</label>
                <mixed-citation publication-type="journal"><name><surname>Babalik</surname><given-names>A</given-names></name>, <name><surname>Ulus</surname><given-names>IH</given-names></name>, <name><surname>Bakirci</surname><given-names>N</given-names></name>, <name><surname>Kuyucu</surname><given-names>T</given-names></name>, <name><surname>Arpag</surname><given-names>H</given-names></name>, <name><surname>Dagyildiz</surname><given-names>L</given-names></name>, <etal>et al</etal><article-title>Pharmacokinetics and serum concentrations of antimycobacterial drugs in adult Turkish patients</article-title>. <source>Int J Tuberc Lung Dis</source>. <year>2013</year>;<volume>17</volume>(<issue>11</issue>):<fpage>1442</fpage>â<lpage>7</lpage>. Epub 2013/10/16. <pub-id pub-id-type="doi">10.5588/ijtld.12.0771</pub-id>
.<?supplied-pmid 24125448?><pub-id pub-id-type="pmid">24125448</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0141002.ref041">
                <label>41</label>
                <mixed-citation publication-type="book"><name><surname>Chigutsa</surname><given-names>E</given-names></name>. <chapter-title>Population pharmacokinetics and pharmacokinetic-pharmacodyamic modeling of antitubercular drugs</chapter-title><publisher-loc>University of Cape Town, SA</publisher-loc><publisher-name>University of Cape Town</publisher-name>; <year>2013</year>.</mixed-citation>
              </ref>
              <ref id="pone.0141002.ref042">
                <label>42</label>
                <mixed-citation publication-type="journal"><name><surname>Peloquin</surname><given-names>CA</given-names></name>, <name><surname>Bulpitt</surname><given-names>AE</given-names></name>, <name><surname>Jaresko</surname><given-names>GS</given-names></name>, <name><surname>Jelliffe</surname><given-names>RW</given-names></name>, <name><surname>Childs</surname><given-names>JM</given-names></name>, <name><surname>Nix</surname><given-names>DE</given-names></name>. <article-title>Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids</article-title>. <source>Antimicrob Agents Chemother</source>. <year>1999</year>;<volume>43</volume>(<issue>3</issue>):<fpage>568</fpage>â<lpage>72</lpage>. Epub 1999/02/27. <?supplied-pmid 10049268?><pub-id pub-id-type="pmid">10049268</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0141002.ref043">
                <label>43</label>
                <mixed-citation publication-type="journal"><name><surname>Peloquin</surname><given-names>CA</given-names></name>, <name><surname>Jaresko</surname><given-names>GS</given-names></name>, <name><surname>Yong</surname><given-names>CL</given-names></name>, <name><surname>Keung</surname><given-names>AC</given-names></name>, <name><surname>Bulpitt</surname><given-names>AE</given-names></name>, <name><surname>Jelliffe</surname><given-names>RW</given-names></name>. <article-title>Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide</article-title>. <source>Antimicrob Agents Chemother</source>. <year>1997</year>;<volume>41</volume>(<issue>12</issue>):<fpage>2670</fpage>â<lpage>9</lpage>. Epub 1998/01/07. <?supplied-pmid 9420037?><pub-id pub-id-type="pmid">9420037</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0141002.ref044">
                <label>44</label>
                <mixed-citation publication-type="journal"><name><surname>Tostmann</surname><given-names>A</given-names></name>, <name><surname>Mtabho</surname><given-names>CM</given-names></name>, <name><surname>Semvua</surname><given-names>HH</given-names></name>, <name><surname>van den Boogaard</surname><given-names>J</given-names></name>, <name><surname>Kibiki</surname><given-names>GS</given-names></name>, <name><surname>Boeree</surname><given-names>MJ</given-names></name>, <etal>et al</etal><article-title>Pharmacokinetics of first-line tuberculosis drugs in Tanzanian patients</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2013</year>;<volume>57</volume>(<issue>7</issue>):<fpage>3208</fpage>â<lpage>13</lpage>. Epub 2013/05/01. <pub-id pub-id-type="doi">10.1128/aac.02599-12</pub-id>
<?supplied-pmid 23629715?><pub-id pub-id-type="pmid">23629715</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0141002.ref045">
                <label>45</label>
                <mixed-citation publication-type="journal"><name><surname>Fahimi</surname><given-names>F</given-names></name>, <name><surname>Tabarsi</surname><given-names>P</given-names></name>, <name><surname>Kobarfard</surname><given-names>F</given-names></name>, <name><surname>Bozorg</surname><given-names>BD</given-names></name>, <name><surname>Goodarzi</surname><given-names>A</given-names></name>, <name><surname>Dastan</surname><given-names>F</given-names></name>, <etal>et al</etal><article-title>Isoniazid, rifampicin and pyrazinamide plasma concentrations 2 and 6 h post dose in patients with pulmonary tuberculosis</article-title>. <source>Int J Tuberc Lung Dis</source>. <year>2013</year>;<volume>17</volume>(<issue>12</issue>):<fpage>1602</fpage>â<lpage>6</lpage>. Epub 2013/11/10. <pub-id pub-id-type="doi">10.5588/ijtld.13.0019</pub-id>
.<?supplied-pmid 24200276?><pub-id pub-id-type="pmid">24200276</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0141002.ref046">
                <label>46</label>
                <mixed-citation publication-type="journal"><name><surname>Tappero</surname><given-names>JW</given-names></name>, <name><surname>Bradford</surname><given-names>WZ</given-names></name>, <name><surname>Agerton</surname><given-names>TB</given-names></name>, <name><surname>Hopewell</surname><given-names>P</given-names></name>, <name><surname>Reingold</surname><given-names>AL</given-names></name>, <name><surname>Lockman</surname><given-names>S</given-names></name>, <etal>et al</etal><article-title>Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana</article-title>. <source>Clin Infect Dis</source>. <year>2005</year>;<volume>41</volume>(<issue>4</issue>):<fpage>461</fpage>â<lpage>9</lpage>. Epub 2005/07/20. <pub-id pub-id-type="doi">10.1086/431984</pub-id>
.<?supplied-pmid 16028152?><pub-id pub-id-type="pmid">16028152</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0141002.ref047">
                <label>47</label>
                <mixed-citation publication-type="journal"><name><surname>Um</surname><given-names>SW</given-names></name>, <name><surname>Lee</surname><given-names>SW</given-names></name>, <name><surname>Kwon</surname><given-names>SY</given-names></name>, <name><surname>Yoon</surname><given-names>HI</given-names></name>, <name><surname>Park</surname><given-names>KU</given-names></name>, <name><surname>Song</surname><given-names>J</given-names></name>, <etal>et al</etal><article-title>Low serum concentrations of anti-tuberculosis drugs and determinants of their serum levels</article-title>. <source>Int J Tuberc Lung Dis</source>. <year>2007</year>;<volume>11</volume>(<issue>9</issue>):<fpage>972</fpage>â<lpage>8</lpage>. Epub 2007/08/21. .<?supplied-pmid 17705974?><pub-id pub-id-type="pmid">17705974</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0141002.ref048">
                <label>48</label>
                <mixed-citation publication-type="journal"><name><surname>Kimerling</surname><given-names>ME</given-names></name>, <name><surname>Phillips</surname><given-names>P</given-names></name>, <name><surname>Patterson</surname><given-names>P</given-names></name>, <name><surname>Hall</surname><given-names>M</given-names></name>, <name><surname>Robinson</surname><given-names>CA</given-names></name>, <name><surname>Dunlap</surname><given-names>NE</given-names></name>. <article-title>Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients</article-title>. <source>Chest</source>. <year>1998</year>;<volume>113</volume>(<issue>5</issue>):<fpage>1178</fpage>â<lpage>83</lpage>. Epub 1998/05/22. .<?supplied-pmid 9596291?><pub-id pub-id-type="pmid">9596291</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0141002.ref049">
                <label>49</label>
                <mixed-citation publication-type="journal"><name><surname>McIlleron</surname><given-names>H</given-names></name>, <name><surname>Rustomjee</surname><given-names>R</given-names></name>, <name><surname>Vahedi</surname><given-names>M</given-names></name>, <name><surname>Mthiyane</surname><given-names>T</given-names></name>, <name><surname>Denti</surname><given-names>P</given-names></name>, <name><surname>Connolly</surname><given-names>C</given-names></name>, <etal>et al</etal><article-title>Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2012</year>;<volume>56</volume>(<issue>6</issue>):<fpage>3232</fpage>â<lpage>8</lpage>. Epub 2012/03/14. <pub-id pub-id-type="doi">10.1128/aac.05526-11</pub-id>
<?supplied-pmid 22411614?><pub-id pub-id-type="pmid">22411614</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0141002.ref050">
                <label>50</label>
                <mixed-citation publication-type="journal"><name><surname>Peloquin</surname><given-names>CA</given-names></name>, <name><surname>Bulpitt</surname><given-names>AE</given-names></name>, <name><surname>Jaresko</surname><given-names>GS</given-names></name>, <name><surname>Jelliffe</surname><given-names>RW</given-names></name>, <name><surname>James</surname><given-names>GT</given-names></name>, <name><surname>Nix</surname><given-names>DE</given-names></name>. <article-title>Pharmacokinetics of pyrazinamide under fasting conditions, with food, and with antacids</article-title>. <source>Pharmacotherapy</source>. <year>1998</year>;<volume>18</volume>(<issue>6</issue>):<fpage>1205</fpage>â<lpage>11</lpage>. Epub 1998/12/17. .<?supplied-pmid 9855317?><pub-id pub-id-type="pmid">9855317</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0141002.ref051">
                <label>51</label>
                <mixed-citation publication-type="journal"><name><surname>Zhu</surname><given-names>M</given-names></name>, <name><surname>Burman</surname><given-names>WJ</given-names></name>, <name><surname>Starke</surname><given-names>JR</given-names></name>, <name><surname>Stambaugh</surname><given-names>JJ</given-names></name>, <name><surname>Steiner</surname><given-names>P</given-names></name>, <name><surname>Bulpitt</surname><given-names>AE</given-names></name>, <etal>et al</etal><article-title>Pharmacokinetics of ethambutol in children and adults with tuberculosis</article-title>. <source>Int J Tuberc Lung Dis</source>. <year>2004</year>;<volume>8</volume>(<issue>11</issue>):<fpage>1360</fpage>â<lpage>7</lpage>. Epub 2004/12/08. .<?supplied-pmid 15581206?><pub-id pub-id-type="pmid">15581206</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
